

# Granahan Funds plc (the "Company")

The Company is an open-ended umbrella investment company with variable capital and segregated liability between its sub-funds and is organised under the laws of Ireland as a public limited company pursuant to the Companies Act 2014, as amended. The Company is authorised by the Central Bank of Ireland pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended) (the “UCITS Regulations”) and Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the “Central Bank UCITS Regulations”). The Company was incorporated on October 3, 2013 under registration number 533587.

## INTERIM REPORT AND UNAUDITED FINANCIAL STATEMENTS

For the financial period ended June 30, 2022

<b>CONTENTS</b>	<b>Page No</b>
Investment Manager Commentary	3 – 10
Schedules of Investments (Unaudited)	11 – 21
Statements of Assets and Liabilities (Unaudited)	22 – 29
Statements of Operations (Unaudited)	30 – 33
Statements of Changes in Net Assets (Unaudited)	34 – 38
Financial Highlights (Unaudited)	39 – 49
Notes to the Financial Statements (Unaudited)	50 – 75
Schedule of Material Portfolio Changes (Unaudited)	76 – 81
Directory	82 – 83

**Granahan US Focused Growth Fund (GUSFGAA)**  
**Interim Report – June 30, 2022**  
**Investment Manager Commentary**

## A Brutal Quarter

The GIM Focused Growth portfolio fell -39.27% for the first half of 2022, lagging the -29.46% drop in the Russell 2000 Growth benchmark. Brutal. The portfolio's shortfall relative to the benchmark was roughly largely attributable to poor stock selection in poorer performing sectors most notably Technology and Consumer Discretionary)

There is a wide range of factors conspiring as headwinds to Focused Growth's investment footprint. And while much of the first half performance challenges can be attributed to these factors - which could be viewed as inherent in the high secular growth territory - there have also been self-inflicted wounds. In particular, I'm self-critical of the large positions we owned in Kornit (KRNT) and Etsy (ETSY). While I have high conviction both companies remain "desert-island worthy," it is now clear that each benefitted more significantly from pandemic tailwinds in 2020 and 2021 than I previously appreciated. Earnings estimates for both companies have been cut (significantly in the case of Kornit, less so in the case of Etsy), and valuation multiples have contracted meaningfully. Because these two were large positions, together they accounted for 686 basis points of negative impact in the quarter. More on these and the other large individual stock contributors below:

### *The Three Largest Relative Detractors in Q2 Were:*

- **Kornit (KRNT)** - Kornit is playing a leading role in digitizing and disrupting the traditional textile and apparel printing sectors. The stock fell 78% YTD (impacting performance by -406 basis points). The company's business was very strong in 2020 and 2021, and it has become apparent that Kornit benefitted from pandemic tailwinds more than we realized. As a result, several of the company's customers have cut back or pushed off orders of both new machines and ink. We believe the company remains well-positioned to capture a large share of a growing market, and we maintain a mid-sized position in the stock.
- **Etsy (ETSY)** - Etsy operates a global online marketplace connecting sellers and consumers of unique and creative goods. ETSY shares fell 66% in ytd, impacting performance by -280 basis points. The company reported decent Q1 results but guided for lower than consensus for Q2. While it was apparent that Etsy's strong 2020 and 2021 results benefitted materially from pandemic-related trends, and Etsy is doing a very impressive job retaining the large number of new customers earned during that period, the headwinds facing the company as the world re-opens are fierce. This has led to earnings estimate cuts for 2022 and 2023 (mid-teens reductions), but even more so, a large contraction in the company's valuation multiple. We are maintaining a large position in ETSY shares, believing the company is well positioned to generate strong earnings and free cash flow growth for the next several years, and that the stock's risk/reward is attractive.
- **Porch (PRCH)** - Operates a software platform serving home inspectors and movers. PRCH shares dropped 83% YTD (impacting performance by -83 bps). We attribute this to three factors: Fears that higher interest rates will hurt the velocity of transactions in the residential home market, which will in turn cause Porch's results to fall short of expectations. Investors shunning stocks of companies that are not profitable and/or free cash flow positive. We anticipate Porch will begin generating positive cash free cash flow in H2 2023. Investors have generally also turned sour on stocks that are in the "PropTech" space and stocks that came public through a SPAC structure. Porch is in both categories. We believe these fears are overdone and have added to our position and hold roughly a 1% position size.

### *The Three Largest Relative Contributors in Q2 Were:*

- **Enphase (ENPH)** - Enphase is a leading provider of complete solar systems primarily for the residential power market. ENPH shares were up 6% in H1 and contributed 68 basis points to relative performance due to the significant drop in the benchmark and our large weight in the stock. We believe Enphase's prospects are excellent and that the company is navigating tricky supply constraints in the current environment. We continue to hold a large position in ENPH shares.

**Granahan US Focused Growth Fund (GUSFGAA)**  
**Interim Report – June 30, 2022**  
**Investment Manager Commentary (continued)**

- **Evolent Health (EVH)** - Evolent Health helps healthcare providers and payers improve care and lower costs by implementing a value-based approach to healthcare. EVH rose 11%, contributing +87 basis points to performance in H1. Over the past two years under new management, Evolent has done a good job executing on its fundamentally strong position in value-based care. We believe this is likely to continue and maintain a mid-sized position in EVH shares.
- **HealthEquity (HQY)** - HealthEquity is the largest outsourced provider of health savings accounts (HSA). The company is well positioned to benefit from the secular shift to consumer-directed benefit plans (CDBP). HQY shares rose 39% (helping performance by +77 basis points) in H1 on investor optimism regarding reopening (this helps HealthEquity as some offerings such as FSA/Commuter benefits are tied to employees returning to the office) and rising interest rates (HealthEquity benefits from higher interest rates since the company earns a float on custodial funds). We believe HQY shares are attractive and modestly added to the position in the quarter, maintaining a mid-sized position.

**These Are the Times That Try Growth Investors' Souls**

Interest rates are up dramatically. Since September 2021, 30 Year fixed mortgage rates have almost doubled from 2.9% to 5.7% (source [Mortgage News Daily](#)), while yields on the two-year constant maturity US Treasuries are up from 0.20% to 3.07% (Bloomberg). Higher interest rates leave investors discounting earnings at a higher rate. If all else were equal, such a big move in rates would be a fierce head wind for secular growth stocks, which investors value based on future earnings. But of course, all else is not equal. Inflation is also up, the Federal Reserve is tightening, and war rages in Ukraine. And, although the U.S. economy has thus far demonstrated resilience to these challenges, the odds of a recession have risen. In fact, many investors are all but certain a recession is coming, if not here already. At a recent conference in Boston, JP Morgan CEO Jamie Dimon stated that his best prediction was that there are about equal one-third odds that the U.S. will: a) avoid a recession; b) experience a narrow recession; c) have a deeper recession. The net result is that the investor sentiment pendulum has swung heavily from greed to fear over the past nine months, and investors have fled asset classes, sectors, and stocks perceived to be riskier and/or longer duration.

**Granahan US Focused Growth Fund (GUSFGAA)**  
**Interim Report – June 30, 2022**  
**Investment Manager Commentary (continued)**

**Here We Are, Uncertainties Abound. What Are We Doing?**

While I've said many times, "I don't have a crystal ball," our baseline assumption is that the odds of a recession or slowdown have gone up, which we incorporate into our bottom-up scenario and valuation analysis. As a reminder, our process seeks to identify Desert Island worthy companies--those we believe are likely to grow to be much larger over the next five to seven years. We then seek to own stock in such companies when the risk/reward and probability-weighted expected returns are attractive.

Today we have on the one hand higher rates and a cloudier macro view, but on the other hand, a significant contraction in valuations. Where does this net out? All things considered I believe that the forward probability-weighted expected returns for the Focused Growth portfolio appear quite attractive. That is not to say stocks can't go lower. Of course, they can. There is no way to know when sentiment will shift from negative to neutral or positive. Finally, as always, I encourage investors to review and adhere to their asset allocation plans.



**Update on Diversity, Equity, and Inclusion**

Two years ago, in my Q2 2020 letter, I discussed Wall Street's too white, too male problem. I wrote about it being a "top of the funnel" challenge which led to too few analysts, portfolio managers, and asset management executives being female and/or people of color. In August of 2020, we were co-founders of the [Wall Street Diversity Accelerator](#) (WSDA) internship program. The goal was to bring more diverse people into the funnel by introducing rising college sophomores and juniors to the asset management industry. That first summer, we had 7 interns and 5 firms participated. It went well, and we got positive feedback from both the interns and the firms. So, we expanded in the summer of 2021, with 15 interns working at 10 firms. Again, the feedback was positive, and we just completed the 2022 WSDA program with 26 interns and 20 asset management or registered investment advisor (RIA) firms participating. Beyond the successful WSDA internships, we are seeing concrete positive results. Many of the interns from 2020 and 2021 are getting terrific jobs/internships at firms ranging from JP Morgan to Morgan Stanley to Vista Equity Partners. While we still have a long, long way to go, I'm pleased to report that we and many others in our industry are beginning to make a slight dent in improving diversity in the investment business. I'll keep you posted.

**Granahan US Focused Growth Fund (GUSFGAA)  
Interim Report – June 30, 2022  
Investment Manager Commentary (continued)**

As always, on behalf of the entire team at Granahan Investment Management, thank you for entrusting us with the management of your capital. Please note that it is managed alongside our own.

Turbulent times and markets aside, I hope you are having an enjoyable summer.

Sincerely,

A handwritten signature in black ink, appearing to read 'A. Beja', with a stylized flourish at the end.

Andrew L. Beja, CFA  
[dbeja@granahan.com](mailto:dbeja@granahan.com)

Disclosure:

*The information provided in this commentary should not be considered a recommendation to purchase or sell any particular security. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that securities sold have not been repurchased. The securities discussed do not represent an account's entire portfolio and, in the aggregate, may represent only a small percentage of an account's portfolio holdings. It should not be assumed that any of the securities transactions or holdings discussed were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the securities discussed herein.*

**Granahan US Small Cap Discoveries Fund (GUSDFUA)**  
**Interim Report – June 30, 2022**  
**Investment Manager Commentary**

**Distinguishing Features**

GIM builds the Small Cap Discoveries UCITS portfolio from the bottom-up with sector weightings secondary to stock selection. The fund focuses on small cap innovation-driven companies, which tend to be concentrated in the Biotech, Life Sciences, and Technology sectors. Since last quarter, the portfolio maintained a significant overweight in Healthcare versus the Russell 2000 Growth benchmark. During the second quarter we reduced our underweight in Technology and Consumer Discretionary and increased our underweight in Industrials. Our relative weightings to benchmark for other sectors were largely unchanged.

**Commentary****Market Environment**

Everything we read today talks about record breaking negative macro-economic indicators, or at least things we haven't seen in 40 or 50 years. When the Chairman of the Federal Reserve stated that "there's no guarantee of a benign outcome" referring to tightening and the possibility of creating a deep recession, markets declined sharply. The Fed hiked interest rates by 50 basis points in May and 75 basis points in June, which was its largest single hike since 1994 - the only other year in 50 years where, like 2022, both stocks and bonds delivered historically low first half returns. Small business sentiment is the lowest in 48 years and consumer sentiment is close to its all-time low of 1991. While the news is not good with a war, high inflation, higher interest rates, a strong dollar and negative GDP growth, we should remember that the stock market is a leading indicator. The small cap growth market has been declining since May of 2021, forecasting the negative macro-economic news and the resultant pressure on earnings growth rates. If GDP growth is as negative this quarter as it was last quarter, we will technically already be in a recession - an odd recession though, as the unemployment rate is still quite low at 3.6%.

**Performance Discussion**

The first half of 2022 began much like the fourth quarter of 2021 wherein high-growth companies were heavily penalized by the market. However, we did see some rotation in June into sectors like Biotech that had been significantly underperforming, which drove a partial recovery in the fund's relative performance for the quarter. GIM's Small Cap Discoveries UCITS returned -34.74% in Q2, lagging its Russell 2000 Growth benchmark's return of 29.46%. Concerns around higher interest rates and inflation continued to pressure multiples for our secular, high growth companies, while fears of a recession intensified during the second quarter. Healthcare was our worst performing sector for the six months largely due to stock selection and also our large overweight. Basic Materials and Financials were the only positives selection effect, all other sectors were negative. We saw a meaningful positive reversal during the month of June in Healthcare and Technology possibly indicating a recognition by investors that these sectors have become significantly oversold.

With respect to LifeCycles, Core Growth, Special Situation, and Pioneers all underperformed.

The largest detractors during the quarter were **ThredUp** (Consumer Discretionary), **Digital Turbine** (Technology), and **Edgio** (Technology), each hit hard due to concerns around consumer spending and specifically softness in eCommerce.

**Hudson Technologies** (Materials), **Distribution Solutions Group** (Industrials), and **Amwell** (Healthcare) were top contributors during the quarter.

**Granahan US Small Cap Discoveries Fund (GUSDFUA)**  
**Interim Report – June 30, 2022**  
**Investment Manager Commentary (continued)**

**Positioning**

The recent underperformance of innovation-driven sectors juxtaposed with ongoing progress in creating life-changing products has created some highly attractive risk/reward tradeoffs in sectors like life sciences and technology. The XBI biotech index (which includes mid- and large-cap companies) appreciated nearly 700% from February 2011 through its peak in February 2021. Since then, the index is down nearly 60%. Small-cap biotech and life science companies have been hit disproportionately hard as investors have abandoned high growth, unprofitable companies in favor of defensive names. We can't call a bottom but we do believe strongly that the risks to small cap growth companies are now being recognized more so than the opportunities, which is a major reversal from the past few years. For example, more than half of the names in the biotech sector traded below \$100M enterprise value during the second quarter 2022, and nearly one-third had negative EVs meaning the market views these franchises as largely worthless. Some will turn out to be just that and we will avoid them. But with this backdrop there are stocks poised for dramatic upside on positive news and we are concentrating around names with such profiles while working hard to find new names with equal or better profiles. While the fund has added a few names with recession-resistant business models, such as discount retailer Grocery Outlet (GO), we are not abandoning or significantly modifying our fundamentals-driven stock picking approach in small-cap growth.

**Outlook**

The Small Cap Discoveries UCITS portfolio leverages GIM's team of experienced portfolio managers who are also sector specialists. We remain committed to our process for finding great long-term growth opportunities by identifying companies early in their lifecycle with disruptive products addressing large markets. The value-creation process for these types of companies plays out over years, making patience and opportunistic position sizing key components of our investing process. We have begun to see some of the benefits of our approach, as evidenced by the ongoing stock recoveries for names like Amwell. And while we don't assume that the volatility we've experienced across sectors will end or even materially abate in the near-term, we will use these periods to concentrate around our highest conviction long-term growth franchises. According to Furey Research, the Russell 2000 Growth shed roughly 40% from its 52-week high during the second quarter, 10% worse than the Russell 2000 Core which itself had its worst year over year performance in its 42- year history during 1H 2022 (Furey June 3, 2022). Furey's work also found that missing the first few weeks of a recovery in small-cap stocks is highly costly to performance, with the message being that maintaining exposure to the group is wise during extreme downside periods such as we've experienced recently. We are concentrating the portfolio around fundamentally strong names poised to outperform during a small-cap recovery as well as over the long term.

As always, we appreciate and thank you for trusting Granahan with the management of your capital.

**Disclosure:**

*The information provided in this commentary should not be considered a recommendation to purchase or sell any particular security. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that securities sold have not been repurchased. The securities discussed do not represent an account's entire portfolio and, in the aggregate, may represent only a small percentage of an account's portfolio holdings. It should not be assumed that any of the securities transactions or holdings discussed were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the securities discussed herein.*



**Granahan US SMID Select Fund (GUSSIGA)**  
**Interim Report – June 30, 2022**  
**Investment Manager Commentary**

**Distinguishing Features**

GIM builds the [SMID Cap Select](#) portfolio from the bottom-up; sector weightings are secondary to stock selection. At quarter-end, the SMID Cap Select portfolio maintained a significant overweight versus the Russell 2500 Growth Index in Information Technology and Communication Services. We are equal weight to the benchmark in Consumer Staples, and Industrials. We are underweight the benchmark in all other sectors, with Materials and Consumer Discretionary being our largest underweights. The portfolio has no exposure to Utilities and Energy.

**Commentary****Market Environment**

Everything we read today talks about record breaking negative macro-economic indicators, or at least things we haven't seen in 40 or 50 years. When the Chairman of the Federal Reserve stated that "there's no guarantee of a benign outcome" referring to tightening and the possibility of creating a deep recession, markets declined sharply. The Fed hiked interest rates by 50 basis points in May and 75 basis points in June, which was its largest single hike since 1994 - the only other year in 50 years where, like 2022, both stocks and bonds delivered historically low first half returns. Small business sentiment is the lowest in 48 years and consumer sentiment is close to its all-time low of 1991. While the news is not good with a war, high inflation, higher interest rates, a strong dollar and negative GDP growth, we should remember that the stock market is a leading indicator. The small cap growth market has been declining since May of 2021, forecasting the negative macro-economic news and the resultant pressure on earnings growth rates. If GDP growth is as negative this quarter as it was last quarter, we will technically already be in a recession - an odd recession though, as the unemployment rate is still quite low at 3.6%.

**Performance**

It was another very tough quarter for performance in the strategy. Our Special Situation stocks were by far our best, with Pioneers next and soundly outperforming Core Growth. In hindsight, we were too early in moving some of our Special Situation weight back into Core Growth, but we are steadfast in our belief that this will be rewarded in the long-term. The Granahan SMID Cap Select strategy returned -39.23%, behind the -29.45% return of its Russell 2500 Growth benchmark. Higher interest rates and inflation resulted in a collapse in multiples, causing major changes in the prices of many of our secular, high growth companies.

The largest detractors during the first half were Core Growth names **Digital Turbine** (Information Technology), **Kornit** (Industrials) and **Esty** (Consumer Discretionary) and Pioneers **Magnite** (Communication Services) and Porch (Information Technology).

On the positive side, the largest contributors for the first half were Core Growth names Euronet (Information Technology), **Enphase Energy** (Information Technology) and Lithia (Consumer Staples). Special Situation holdings **Evolent Health** (Health Care) and **Chart Industries** (Industrials) finish out the top five.

**Positioning**

Historically, we have seen faster growing companies command higher valuations than lower growth companies, but in today's market, that's not consistently been the case. It's hard to gauge whether we could already be in a recession today, or whether we are just in the early stages of peak inflation. While wages and rents continue to rise, it appears that physical goods prices began coming down across the board during most of Q2. We think this bodes well for lower inflation rates eventually. While it is likely that some earnings expectations still need to move lower from here, it is possible that the market may be already discounting a recession.

**Granahan US SMID Select Fund (GUSSIGA)**  
**Interim Report – June 30, 2022**  
**Investment Manager Commentary (continued)**

As we have said before, we do not have a crystal ball in terms of when the recovery will occur. Instead, we are remaining vigilant in our quest for finding stocks with the best risk/reward dynamics over the medium to long-term. Ultimately, we believe that growth rates will normalize, and inflation rates will come back down. This tends to favor growth stocks, especially the ones that can continue to grow faster than GDP and help their clients lower costs and improve productivity. Many of the negative macroeconomic dynamics we are grappling with today are not sustainable and the portfolio is positioned to capitalize from improving earnings in companies that should have very strong long-term secular growth ahead.

**Porch** (Pioneer, Technology) has 25% of its business tied to housing transactions and its stock is down over 80% year to date. We believe Porch can grow its revenues at a 20% plus CAGR for the next five years and we have added to our position. **Vita Coco** (Core Growth, Consumer Staples) became victim to high shipping prices, yet still has been an outperformer year to date. We are seeing it trade at a massive discount to traditional valuations for other Consumer Staples companies growing revenues at a similar 15% rate. Combined, we have two great growth companies whose prospects over the longer term should be much better than they are today while still exhibiting great growth and taking market share. While we clearly did not have this right in the portfolio last quarter, we feel good about our companies' fundamentals. Porch and Vita Coco are good examples of why..

#### **Outlook**

The current small-cap bear market has coincided with a period of solid company fundamentals and growing profits. Small-cap growth profits grew significantly over the last twelve-month period in which the small-cap growth index fell 33%. This divergence has led to a significant reduction in small-cap valuations. The market is forecasting a slowdown in revenue and earnings growth for the next several years, but even cutting growth rates significantly from the 66% we have seen over the last year to 20%, valuations look extremely interesting. The Russell 2000 Growth Index now has a lowered average PE on the next twelve months earnings estimates of 17.5x, down from its 32.5x valuation a year ago. We are adding to stocks in the portfolio that have no need for a lift in valuation, as the compounding of their earnings growth should bring positive results to their stock prices. The risk, of course, is that we could be wrong on our earnings estimates.

At the forefront of many investors' minds are questions concerning inflation, Fed policies, recession and when will the market recover. Based on our decades of investment experience, a market low is impossible to predict, and frankly, trying to answer these questions may be counterproductive. What we do know is that returns from bear market bottoms have been exceptionally strong historically, and it's not uncommon for the market's best days to soon follow the worst. Our focus is on talking with the management teams at our companies to ensure they have strong secular growth prospects.

As always, we appreciate and thank you for trusting Granahan with the management of your capital.

#### Disclosure:

*The information provided in this commentary should not be considered a recommendation to purchase or sell any particular security. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that securities sold have not been repurchased. The securities discussed do not represent an account's entire portfolio and, in the aggregate, may represent only a small percentage of an account's portfolio holdings. It should not be assumed that any of the securities transactions or holdings discussed were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the securities discussed herein.*

**GRANAHAH FUNDS PLC**

**GRANAHAH US FOCUSED GROWTH FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED)  
June 30, 2022**

(expressed in USD) Description	Quantity	Currency	Fair Value	% Net assets
<b>A) TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING</b>				
<b>1) LISTED SECURITIES : SHARES</b>				
<b>BAHAMAS</b>				
OneSpaWorld Holdings Ltd	663,534	USD	4,757,539	0.94
			<u>4,757,539</u>	<u>0.94</u>
<b>GUERNSEY</b>				
Genius Sports Ltd	2,003,731	USD	4,508,395	0.89
			<u>4,508,395</u>	<u>0.89</u>
<b>ISRAEL</b>				
Kornit Digital Ltd	493,464	USD	15,642,809	3.08
Stratasys Ltd	899,611	USD	16,858,710	3.32
			<u>32,501,519</u>	<u>6.40</u>
<b>LUXEMBOURG</b>				
Globant SA	22,229	USD	3,867,846	0.76
			<u>3,867,846</u>	<u>0.76</u>
<b>UNITED STATES (U.S.A.)</b>				
Appian Corp	28,998	USD	1,373,345	0.27
Axon Enterprise Inc*	313,035	USD	29,165,471	5.74
Azenta Inc	260,484	USD	18,780,896	3.69
Bright Horizons Family Solutions Inc	122,212	USD	10,329,358	2.03
Bumble Inc	386,003	USD	10,865,984	2.14
Chegg Inc	70,450	USD	1,323,051	0.26
CoStar Group Inc*	611,422	USD	36,936,003	7.27
Coupa Software Inc	129,044	USD	7,368,412	1.45
Domo Inc	269,912	USD	7,503,554	1.48
Enovix Corp	946,672	USD	8,434,848	1.66
Enphase Energy Inc*	150,181	USD	29,321,338	5.77
Etsy Inc*	355,802	USD	26,048,264	5.12
EverQuote Inc	577,676	USD	5,106,656	1.00
Evolent Health Inc	605,203	USD	18,585,784	3.66

\* Securities represent more than 5% of the total Net Asset Value, therefore exposed to concentration risk.

**GRANAHAN FUNDS PLC**

**GRANAHAN US FOCUSED GROWTH FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED) – continued  
June 30, 2022**

(expressed in USD) Description	Quantity	Currency	Fair Value	% Net assets
<b>A) TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING (continued)</b>				
<b>1) LISTED SECURITIES : SHARES (continued)</b>				
UNITED STATES (U.S.A.) (continued)				
First Watch Restaurant Group Inc	329,020	USD	4,744,468	0.93
HealthEquity Inc	270,682	USD	16,617,168	3.27
Life Time Group Holdings Inc	1,204,736	USD	15,517,000	3.05
Liquidity Services Inc	828,054	USD	11,129,046	2.19
LivePerson Inc	513,491	USD	7,260,763	1.43
Lovesac Co	333,121	USD	9,160,828	1.80
Magnite Inc	1,017,345	USD	9,034,024	1.78
OSI Systems Inc	173,318	USD	14,808,290	2.91
Paycom Software Inc*	145,031	USD	40,626,084	7.99
Paylocity Holding Corp	66,312	USD	11,566,139	2.27
Porch Group Inc	2,147,622	USD	5,497,912	1.08
ShotSpotter Inc	208,934	USD	5,622,414	1.11
Sprout Social Inc	90,509	USD	5,255,858	1.03
SPS Commerce Inc*	323,768	USD	36,601,972	7.20
Toast Inc	1,260,380	USD	16,309,317	3.21
Victory Capital Holdings Inc	371,193	USD	8,945,751	1.76
Workiva Inc	199,564	USD	13,169,228	2.59
Zeta Global Holdings Corp	2,281,582	USD	10,312,751	2.03
			<u>453,321,977</u>	<u>89.17</u>
<b>TOTAL LISTED SECURITIES : SHARES</b>			<u>498,957,276</u>	<u>98.16</u>
<b><u>TOTAL TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING</u></b>			<b><u>498,957,276</u></b>	<b><u>98.16</u></b>
<b>TOTAL INVESTMENTS</b>			<b>498,957,276</b>	<b>98.16</b>
<b>OTHER ASSETS</b>			<b>22,069,294</b>	<b>4.34</b>
<b>OTHER LIABILITIES</b>			<b>(12,723,573)</b>	<b>(2.50)</b>
<b>NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES</b>			<b><u>508,302,997</u></b>	<b><u>100.00</u></b>

\* Securities represent more than 5% of the total Net Asset Value, therefore exposed to concentration risk.

GRANAHAN FUNDS PLC

**GRANAHAN US FOCUSED GROWTH FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED) - continued  
June 30, 2022**

At June 30, 2022 sector diversification of the Fund was as follows:

	% of Net Assets	Value
<b>Common stock</b>		
Aerospace & Defense	5.74	29,165,471
Diversified Consumer Services	5.34	27,169,409
Diversified Financials Services	3.73	18,952,058
Electronic Equipment Instruments & Components	6.23	31,667,000
Health Care Providers & Services	3.27	16,617,168
Health Care Technology	3.66	18,585,784
Hotels Restaurants & Leisure	1.87	9,502,007
Household Durables	1.80	9,160,828
Interactive Media & Services	1.00	5,106,656
Internet & Direct Marketing Retail	7.31	37,177,310
Life Sciences Tools & Services	3.69	18,780,896
Machinery	3.08	15,642,809
Media	1.78	9,034,024
Professional Services	7.27	36,936,003
Semiconductors & Semiconductor Equipment	7.43	37,756,186
Software	34.96	177,703,667
<b>TOTAL INVESTMENTS</b>	<b>98.16</b>	<b>498,957,276</b>
Other Assets and Cash in Excess of Liabilities	1.84	9,345,721
<b>TOTAL NET ASSETS</b>	<b>100.00</b>	<b>508,302,997</b>

**Analysis of Total Assets**

	% of Total Assets
Transferable Securities Admitted To An Official Stock Exchange or traded on a regulated market	95.76
Current Assets	4.24
<b>TOTAL</b>	<b>100.00</b>

**GRANAHAN FUNDS PLC**

**GRANAHAN US SMALL CAP DISCOVERIES FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED)  
June 30, 2022**

(expressed in USD) Description	Quantity	Currency	Fair Value	% Net assets
<b>A) TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING</b>				
<b>1) LISTED SECURITIES : SHARES</b>				
<b>BERMUDA ISLANDS</b>				
Kiniksa Pharmaceuticals Ltd	59,350	USD	575,102	1.99
			<u>575,102</u>	<u>1.99</u>
<b>CANADA</b>				
Zymeworks Inc	35,800	USD	189,740	0.66
			<u>189,740</u>	<u>0.66</u>
<b>GREAT BRITAIN</b>				
Luxfer Holdings PLC	46,178	USD	698,211	2.42
			<u>698,211</u>	<u>2.42</u>
<b>IRELAND</b>				
Prothena Corp PLC	19,850	USD	538,928	1.87
			<u>538,928</u>	<u>1.87</u>
<b>SWITZERLAND</b>				
CRISPR Therapeutics AG	9,010	USD	547,538	1.89
			<u>547,538</u>	<u>1.89</u>
<b>UNITED STATES (U.S.A.)</b>				
908 Devices Inc	35,050	USD	721,680	2.50
Akoya Biosciences Inc	13,367	USD	171,766	0.59
Alta Equipment Group Inc	66,400	USD	595,608	2.06
American Well Corp	185,150	USD	799,847	2.77
Apellis Pharmaceuticals Inc	13,500	USD	610,470	2.11
Arcus Biosciences Inc	32,266	USD	817,619	2.83
Array Technologies Inc	31,200	USD	343,512	1.19
Beam Therapeutics Inc	4,501	USD	174,234	0.60
BioLife Solutions Inc	12,759	USD	176,202	0.61
Blueprint Medicines Corp	12,800	USD	646,528	2.24
Caribou Biosciences Inc	38,878	USD	211,108	0.73

**GRANAHAN FUNDS PLC**

**GRANAHAN US SMALL CAP DISCOVERIES FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED) – continued  
June 30, 2022**

(expressed in USD) Description	Quantity	Currency	Fair Value	% Net assets
<b>A) TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING (continued)</b>				
<b>1) LISTED SECURITIES : SHARES (continued)</b>				
UNITED STATES (U.S.A.) (continued)				
Castle Biosciences Inc	15,868	USD	348,303	1.21
ChemoCentryx Inc	21,650	USD	536,487	1.86
Columbus McKinnon Corp	17,550	USD	497,894	1.72
CorVel Corp	3,750	USD	552,263	1.91
CryoPort Inc	14,469	USD	448,250	1.55
Digital Turbine Inc	20,000	USD	349,400	1.21
Distribution Solutions Group Inc	14,773	USD	759,183	2.63
Douglas Dynamics Inc	22,905	USD	658,290	2.28
Edgio Inc	181,050	USD	418,226	1.45
Fate Therapeutics Inc	23,700	USD	587,286	2.03
Grocery Outlet Holding Corp	12,850	USD	547,796	1.90
Heska Corp	5,350	USD	505,629	1.75
iCAD Inc	20,376	USD	81,504	0.28
ImmunoGen Inc	159,600	USD	718,199	2.49
Innovative Industrial Properties Inc	4,104	USD	450,906	1.56
Intellia Therapeutics Inc	12,170	USD	629,919	2.18
Kezar Life Sciences Inc	27,500	USD	227,425	0.79
Kinsale Capital Group Inc	3,350	USD	769,294	2.66
Magnite Inc	50,909	USD	452,072	1.56
Materion Corp	5,947	USD	438,472	1.52
Mesa Laboratories Inc	3,247	USD	662,193	2.29
Natera Inc	12,750	USD	451,860	1.56
OrthoPediatrics Corp	18,226	USD	786,452	2.72
Pacific Biosciences of California Inc	61,350	USD	271,167	0.94
Perficient Inc	6,200	USD	568,478	1.97
Pliant Therapeutics Inc	36,940	USD	295,889	1.02
Portillo's Inc	49,400	USD	807,689	2.79
PROS Holdings Inc	30,886	USD	810,139	2.80
Quanterix Corp	18,500	USD	299,515	1.04
Revance Therapeutics Inc	34,550	USD	477,481	1.65
Rush Enterprises Inc	11,350	USD	547,070	1.89
Shockwave Medical Inc	3,600	USD	688,212	2.38
Silk Road Medical Inc	10,050	USD	365,720	1.27
Sprout Social Inc	6,650	USD	386,166	1.34
Stoke Therapeutics Inc	21,450	USD	283,355	0.98
Stoneridge Inc	26,100	USD	447,615	1.55

GRANAHAN FUNDS PLC

**GRANAHAN US SMALL CAP DISCOVERIES FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED) – continued  
June 30, 2022**

(expressed in USD) Description	Quantity	Currency	Fair Value	% Net assets
<b>A) TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING (continued)</b>				
<b>1) LISTED SECURITIES : SHARES (continued)</b>				
UNITED STATES (U.S.A.) (continued)				
Texas Capital Bancshares Inc	8,950	USD	471,128	1.63
ThredUp Inc	222,350	USD	555,875	1.92
Veeco Instruments Inc	33,200	USD	644,080	2.23
Veracyte Inc	19,991	USD	397,821	1.38
Vericel Corp	18,988	USD	478,118	1.65
			25,941,395	89.77
<b>TOTAL LISTED SECURITIES : SHARES</b>			28,490,914	98.60
<b><u>TOTAL TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING</u></b>			<b>28,490,914</b>	<b>98.60</b>
<b>B) OTHER TRANSFERABLE SECURITIES</b>				
<b>1) OTHER TRANSFERABLE SECURITIES : SHARES</b>				
UNITED STATES (U.S.A.)				
Contra Flexion Therape Npv	99,583	USD	996	-
			996	-
<b>TOTAL OTHER TRANSFERABLE SECURITIES : SHARES</b>			996	-
<b><u>TOTAL OTHER TRANSFERABLE SECURITIES</u></b>			<b>996</b>	<b>-</b>
<b>TOTAL INVESTMENTS</b>			<b>28,491,910</b>	<b>98.60</b>
<b>OTHER ASSETS</b>			<b>2,475,115</b>	<b>8.57</b>
<b>OTHER LIABILITIES</b>			<b>(2,072,716)</b>	<b>(7.17)</b>
<b>NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES</b>			<b>28,894,309</b>	<b>100.00</b>



GRANAHAN FUNDS PLC

**GRANAHAN US SMALL CAP DISCOVERIES FUND**  
**SCHEDULE OF INVESTMENTS (UNAUDITED) – continued**  
**June 30, 2022**

At June 30, 2022 sector diversification of the Fund was as follows:

	% of Net Assets	Value
<b>Common stock</b>		
Basic Materials	1.52	438,472
Consumer Discretionary	10.22	2,953,857
Consumer Staples	1.9	547,796
Energy	1.19	343,512
Financials	4.29	1,240,422
Health Care	52.47	15,164,363
Industrials	12.89	3,724,021
Real Estate	1.56	450,906
Technology	12.56	3,628,561
<b>TOTAL INVESTMENTS</b>	<b>98.60</b>	<b>28,491,910</b>
Other Assets and Cash in Excess of Liabilities	1.40	402,399
<b>TOTAL NET ASSETS</b>	<b>100.00</b>	<b>28,894,309</b>

**Analysis of Total Assets**

	% of Total Assets
Transferable Securities Admitted To An Official Stock Exchange or traded on a regulated market	92.01
Other Transferable Securities	-
Current Assets	7.99
<b>TOTAL</b>	<b>100.00</b>

**GRANAHAN FUNDS PLC**

**GRANAHAN US SMID SELECT FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED)  
June 30, 2022**

(expressed in USD) Description	Quantity	Currency	Fair Value	% Net assets
<b>A) TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING</b>				
<b>1) LISTED SECURITIES : SHARES</b>				
<b>CANADA</b>				
Neo Performance Materials Inc	147,512	CAD	1,424,467	0.35
Sierra Wireless Inc	159,437	USD	3,730,826	0.91
			<u>5,155,293</u>	<u>1.26</u>
<b>CAYMAN ISLANDS</b>				
Ambarella Inc	92,201	USD	6,035,477	1.47
			<u>6,035,477</u>	<u>1.47</u>
<b>ISRAEL</b>				
Inmode Ltd	89,792	USD	2,012,239	0.49
Kornit Digital Ltd*	723,984	USD	22,950,293	5.60
			<u>24,962,532</u>	<u>6.09</u>
<b>NETHERLANDS</b>				
Affimed NV	1,323,422	USD	3,665,879	0.89
			<u>3,665,879</u>	<u>0.89</u>
<b>UNITED STATES (U.S.A.)</b>				
Ameresco Inc	156,963	USD	7,151,234	1.74
Array Technologies Inc*	2,918,383	USD	32,131,396	7.83
Axon Enterprise Inc	74,076	USD	6,901,661	1.68
Castle Biosciences Inc	180,993	USD	3,972,796	0.97
Chart Industries Inc	107,505	USD	17,994,187	4.39
Chicken Soup For The Soul Entertainment Inc	473,117	USD	3,505,797	0.85
CryoPort Inc	79,708	USD	2,469,354	0.60
Darling Ingredients Inc	127,887	USD	7,647,643	1.86
Definitive Healthcare Corp	85,961	USD	1,971,086	0.48
Digital Turbine Inc*	1,384,259	USD	24,183,005	5.90
Edgio Inc	1,096,442	USD	2,532,781	0.62
Enphase Energy Inc*	130,836	USD	25,544,421	6.23
EPAM Systems Inc	32,866	USD	9,688,239	2.36
Etsy Inc	82,832	USD	6,064,131	1.48

\* Securities represent more than 5% of the total Net Asset Value, therefore exposed to concentration risk.

**GRANAHAN FUNDS PLC**

**GRANAHAN US SMID SELECT FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED) - continued  
June 30, 2022**

(expressed in USD) Description	Quantity	Currency	Fair Value	% Net assets
<b>A) TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING (continued)</b>				
<b>1) LISTED SECURITIES : SHARES (continued)</b>				
UNITED STATES (U.S.A.) (continued)				
Euronet Worldwide Inc	188,006	USD	18,911,524	4.61
Evolent Health Inc*	834,593	USD	25,630,351	6.25
Expedia Group Inc	22,269	USD	2,111,769	0.52
Figs Inc	792,862	USD	7,222,973	1.76
Gentherm Inc	117,608	USD	7,339,915	1.79
Hagerty Inc	665,389	USD	7,645,320	1.86
iCAD Inc	689,152	USD	2,756,608	0.67
Kulicke & Soffa Industries Inc	344,279	USD	14,738,584	3.59
LendingTree Inc	135,316	USD	5,929,547	1.45
Lithia Motors Inc	35,072	USD	9,638,136	2.35
Littelfuse Inc	16,882	USD	4,288,703	1.05
Magnite Inc*	3,230,737	USD	28,688,944	6.99
Match Group Inc	59,448	USD	4,142,931	1.01
Natera Inc	191,790	USD	6,797,038	1.66
PAR Technology Corp	61,897	USD	2,320,519	0.57
Porch Group Inc	1,696,544	USD	4,343,153	1.06
Power Integrations Inc	33,348	USD	2,501,433	0.61
Pure Storage Inc	236,844	USD	6,089,259	1.48
Quanterix Corp	226,056	USD	3,659,847	0.89
Repligen Corp	35,161	USD	5,710,146	1.39
Revolve Group Inc	94,704	USD	2,453,781	0.60
Silergate Capital Corp	75,846	USD	4,060,036	0.99
Stoneridge Inc	123,307	USD	2,114,715	0.52
Varonis Systems Inc	172,803	USD	5,066,584	1.24
Veracyte Inc	657,296	USD	13,080,190	3.19
Vicor Corp	77,583	USD	4,246,118	1.04
Vita Coco Co Inc	1,099,392	USD	10,763,048	2.62
WillScot Mobile Mini Holdings Corp	182,441	USD	5,914,737	1.44
			<u>369,923,640</u>	<u>90.19</u>
<b>TOTAL LISTED SECURITIES : SHARES</b>			<u>409,742,821</u>	<u>99.90</u>
<b><u>TOTAL TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL STOCK EXCHANGE LISTING</u></b>			<b><u>409,742,821</u></b>	<b><u>99.90</u></b>

\* Securities represent more than 5% of the total Net Asset Value, therefore exposed to concentration risk.

**GRANAHAN FUNDS PLC**

**GRANAHAN US SMID SELECT FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED) - continued  
June 30, 2022**

<b>(expressed in USD) Description</b>	<b>Fair Value</b>	<b>% Net assets</b>
<b>TOTAL INVESTMENTS</b>	<b>409,742,821</b>	<b>99.90</b>
<b>OTHER ASSETS</b>	<b>8,269,328</b>	<b>2.02</b>
<b>OTHER LIABILITIES</b>	<b>(7,870,734)</b>	<b>(1.92)</b>
<b>NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES</b>	<b>410,141,415</b>	<b>100.00</b>

**GRANAHAN FUNDS PLC**

**GRANAHAN US SMID SELECT FUND  
SCHEDULE OF INVESTMENTS (UNAUDITED) - continued  
June 30, 2022**

At June 30, 2022 sector diversification of the Fund was as follows:

	<b>% of Net Assets</b>	<b>Value</b>
<b>Common stock</b>		
Communication Services	8.01	32,831,875
Consumer Discretionary	9.86	40,451,217
Consumer Staples	4.49	18,410,691
Financials	4.30	17,634,903
Health Care	17.49	71,725,534
Industrials	15.89	65,158,230
Information Technology	39.51	162,105,904
Materials	0.35	1,424,467
<b>TOTAL INVESTMENTS</b>	<b>99.90</b>	<b>409,742,821</b>
Other Assets and Cash in Excess of Liabilities	0.10	398,594
<b>TOTAL NET ASSETS</b>	<b>100.00</b>	<b>410,141,415</b>

**Analysis of Total Assets**

	<b>% of Total Assets</b>
Transferable Securities Admitted To An Official Stock Exchange or traded on a regulated market	98.02
Current Assets	1.98
<b>TOTAL</b>	<b>100.00</b>

**GRANAHAN FUNDS PLC**

**STATEMENT OF ASSETS AND LIABILITIES (UNAUDITED)**  
**As of June 30, 2022**

	<b>Granahan US Focused Growth Fund June 30, 2022</b>	<b>Granahan US Focused Growth Fund December 31, 2021</b>
<b>Assets</b>		
Investments, at identified cost	\$498,957,276	\$766,387,483
Investments in securities, at fair value (See note 9)	\$498,957,276	\$941,161,320
Cash and cash equivalents (See note 10)	14,019,608	15,610,658
Receivable for subscriptions	65,168	761,875
Receivable for securities sold	7,657,324	-
Prepaid expenses and other assets	195,868	-
Receivable from Investment Manager (See note 5)	131,326	343,492
<b>Total assets</b>	<b>521,026,570</b>	<b>957,877,345</b>
<b>Liabilities</b>		
Payable for securities purchased	1,989,499	-
Payable for fund shares redeemed	9,321,544	1,513,344
Payable to Investment Manager (See note 5)	1,268,947	2,246,137
Manager fees payable (See note 5)	30,650	56,066
Directors fees payable	24,338	3,890
Auditor fees payable	7,783	1,244
Performance fees payable (See note 5)	-	990,243
Other accrued expenses	80,812	77,897
<b>Total liabilities</b>	<b>12,723,573</b>	<b>4,888,821</b>
<b>Net assets</b>	<b>\$508,302,997</b>	<b>\$952,988,524</b>
<b>Net assets consist of</b>		
Paid in capital	\$437,047,655	\$539,533,881
Undistributed net investment loss	(26,216,280)	(23,556,622)
Accumulated net realized gain on investments and foreign currency related transactions	225,220,678	261,286,305
Net unrealized (depreciation)/appreciation on investments and foreign currency related transactions	(127,749,056)	175,724,960
<b>Net assets</b>	<b>\$508,302,997</b>	<b>\$952,988,524</b>

The accompanying notes are an integral part of these financial statements.

# GRANAHAN FUNDS PLC

## STATEMENT OF ASSETS AND LIABILITIES (UNAUDITED) – continued As of June 30, 2022

	<b>Granahan US Focused Growth Fund June 30, 2022</b>	<b>Granahan US Focused Growth Fund December 31, 2021</b>
<b>Class A EUR Accumulating</b>		
Shares issued (See note 3)	22,000.00	22,000.00
Net asset value per share	€6.06	€9.28
<b>Class A GBP Accumulating</b>		
Shares issued (See note 3)	1,075,045.07	1,212,791.96
Net asset value per share	£11.21	£16.76
<b>Class A USD Accumulating</b>		
Shares issued (See note 3)	258,488.05	299,760.50
Net asset value per share	\$317.86	\$528.75
<b>Class A USD Distributing</b>		
Shares issued (See note 3)	41,365.40	47,231.76
Net asset value per share	\$126.31	\$210.11
<b>Class F EUR Accumulating</b>		
Shares issued (See note 3)	101,644.46	156,462.89
Net asset value per share	€12.53	€19.21
<b>Class F GBP Accumulating</b>		
Shares issued (See note 3)	4,204.69	10,133.03
Net asset value per share	£8.38	£12.55
<b>Class I EUR Accumulating</b>		
Shares issued (See note 3)	1,881,011.19	6,748,435.69
Net asset value per share	€6.49	€9.93
<b>Class I GBP Accumulating</b>		
Shares issued (See note 3)	2,071,869.54	2,069,855.25
Net asset value per share	£10.69	£15.97

The accompanying notes are an integral part of these financial statements.

**GRANAHAN FUNDS PLC**

**STATEMENT OF ASSETS AND LIABILITIES (UNAUDITED) – continued**  
**As of June 30, 2022**

	<b>Granahan US Focused Growth Fund</b>	<b>Granahan US Focused Growth Fund</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Class I USD Accumulating</b>		
Shares issued (See note 3)	14,454,192.04	10,294,662.56
Net asset value per share	\$14.54	\$24.16
<b>Class I USD Distributing</b>		
Shares issued (See note 3)	6,804,413.81	7,293,588.69
Net asset value per share	\$14.53	\$24.15
<b>Class P USD Accumulating*</b>		
Shares issued (See note 3)	-	2,990,259.04
Net asset value per share	-	\$23.03
<b>Class P1 USD Accumulating</b>		
Shares issued (See note 3)	6,656,225.00	9,956,225.00
Net asset value per share	\$8.41	\$13.91

\* This share class was terminated on April 20, 2022.

The accompanying notes are an integral part of these financial statements.



**GRANAHAN FUNDS PLC**

**STATEMENT OF ASSETS AND LIABILITIES (UNAUDITED) – continued**  
**As of June 30, 2022**

	<b>Granahan US Small Cap Discoveries Fund</b>	<b>Granahan US Small Cap Discoveries Fund</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Assets</b>		
Investments, at identified cost	\$37,139,735	\$39,287,726
Investments in securities, at fair value (See note 9)	\$28,491,910	\$43,946,097
Cash and cash equivalents (See note 10)	544,410	1,542,462
Receivable for subscriptions	8,051	-
Dividends and interest receivable	5,044	7,968
Receivable for securities sold	1,897,587	-
Prepaid expenses and other assets	13,491	-
Receivable from Investment Manager (See note 5)	6,532	41,322
<b>Total assets</b>	<b>30,967,025</b>	<b>45,537,849</b>
<b>Liabilities</b>		
Payable for securities purchased	1,991,230	-
Payable for fund shares redeemed	8,635	256,070
Payable to Investment Manager (See note 5)	54,495	83,626
Manager fees payable (See note 5)	1,652	2,483
Directors fees payable	1,264	181
Auditor fees payable	404	58
Other accrued expenses	15,036	19,984
<b>Total liabilities</b>	<b>2,072,716</b>	<b>362,402</b>
<b>Net assets</b>	<b>\$28,894,309</b>	<b>\$45,175,447</b>
<b>Net assets consist of</b>		
Paid in capital	\$31,185,169	\$31,555,384
Undistributed net investment loss	(1,066,915)	(899,111)
Accumulated net realized gain on investments and foreign currency related transactions	7,200,380	9,664,403
Net unrealized (depreciation)/appreciation on investments and foreign currency related transactions	(8,424,325)	4,854,771
<b>Net assets</b>	<b>\$28,894,309</b>	<b>\$45,175,447</b>

The accompanying notes are an integral part of these financial statements.

**GRANAHAN FUNDS PLC**

**STATEMENT OF ASSETS AND LIABILITIES (UNAUDITED) – continued**  
**As of June 30, 2022**

	<b>Granahan US Small Cap Discoveries Fund</b>	<b>Granahan US Small Cap Discoveries Fund</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Class Founder GBP Accumulating</b>		
Shares issued (See note 3)	1,018.43	1,447.67
Net asset value per share	£12.28	£17.11
 <b>Class Founder USD Accumulating</b>		
Shares issued (See note 3)	2,109,391.06	2,128,499.06
Net asset value per share	\$13.69	\$21.21

The accompanying notes are an integral part of these financial statements.

**GRANAHAN FUNDS PLC**

**STATEMENT OF ASSETS AND LIABILITIES (UNAUDITED) – continued**  
**As of June 30, 2022**

	<b>Granahan US SMID Select Fund June 30, 2022</b>	<b>Granahan US SMID Select Fund December 31, 2021</b>
<b>Assets</b>		
Investments, at identified cost	\$588,744,796	\$581,009,333
Investments in securities, at fair value (See note 9)	\$409,742,821	\$633,591,636
Cash and cash equivalents (See note 10)	4,625,339	4,692,809
Receivable for subscriptions	46,693	915,736
Dividends and interest receivable	41,620	48,477
Receivable for securities sold	3,275,300	-
Prepaid expenses and other assets	132,900	-
Receivable from Investment Manager (See note 5)	147,476	234,162
<b>Total assets</b>	<b>418,012,149</b>	<b>639,482,820</b>
<b>Liabilities</b>		
Payable for securities purchased	2,566,020	82,349
Payable for fund shares redeemed	4,154,562	344,279
Payable to Investment Manager (See note 5)	1,041,536	1,526,182
Manager fees payable (See note 5)	24,580	35,270
Directors fees payable	18,288	2,534
Auditor fees payable	5,848	810
Other accrued expenses	59,900	55,564
<b>Total liabilities</b>	<b>7,870,734</b>	<b>2,046,988</b>
<b>Net assets</b>	<b>\$410,141,415</b>	<b>\$637,435,832</b>
<b>Net assets consist of</b>		
Paid in capital	\$450,927,897	\$421,120,896
Undistributed net investment loss	(10,081,778)	(7,605,868)
Accumulated net realized gain on investments and foreign currency related transactions	147,075,830	170,356,569
Net unrealized (depreciation)/appreciation on investments and foreign currency related transactions	(177,780,534)	53,564,235
<b>Net assets</b>	<b>\$410,141,415</b>	<b>\$637,435,832</b>

The accompanying notes are an integral part of these financial statements.

**GRANAHAN FUNDS PLC**

**STATEMENT OF ASSETS AND LIABILITIES (UNAUDITED) – continued**  
**As of June 30, 2022**

	<b>Granahan US SMID Select Fund</b>	<b>Granahan US SMID Select Fund</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Class A GBP Accumulating</b>		
Shares issued (See note 3)	6,072.63	32,684.48
Net asset value per share	£69.30	£103.24
<b>Class A GBP Distributing</b>		
Shares issued (See note 3)	750.00	750.00
Net asset value per share	£66.60	£99.21
<b>Class A USD Accumulating</b>		
Shares issued (See note 3)	173,379.97	175,605.42
Net asset value per share	\$62.12	\$102.91
<b>Class I GBP Accumulating</b>		
Shares issued (See note 3)	1,740,593.51	1,568,342.47
Net asset value per share	£149.63	£222.78
<b>Class I GBP Distributing</b>		
Shares issued (See note 3)	534,458.73	541,967.95
Net asset value per share	£82.86	£123.36
<b>Class I USD Accumulating</b>		
Shares issued (See note 3)	293,646.75	322,673.70
Net asset value per share	\$72.46	\$119.95
<b>Class I USD Distributing</b>		
Shares issued (See note 3)	90,578.51	104,751.19
Net asset value per share	\$72.52	\$120.05

The accompanying notes are an integral part of these financial statements.

**GRANAHAN FUNDS PLC**

**STATEMENT OF ASSETS AND LIABILITIES (UNAUDITED) – continued**  
**As of June 30, 2022**

	<b>Total</b>	<b>Total</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Assets</b>		
Investments, at identified cost	\$1,124,841,807	\$1,386,684,542
Investments in securities, at fair value (See note 9)	\$937,192,007	\$1,618,699,053
Cash and cash equivalents (See note 10)	19,189,357	21,845,929
Receivable for subscriptions	119,912	1,677,611
Dividends and interest receivable	46,664	56,445
Receivable for securities sold	12,830,211	-
Prepaid expenses and other assets	342,259	-
Receivable from Investment Manager (See note 5)	285,334	618,976
<b>Total assets</b>	<b>970,005,744</b>	<b>1,642,898,014</b>
<b>Liabilities</b>		
Payable for securities purchased	6,546,749	82,349
Payable for fund shares redeemed	13,484,741	2,113,693
Payable to Investment Manager (See note 5)	2,364,978	3,855,945
Manager fees payable (See note 5)	56,882	93,819
Directors fees payable	43,890	6,605
Auditor fees payable	14,035	2,112
Performance fees payable (See note 5)	-	990,243
Other accrued expenses	155,748	153,445
<b>Total liabilities</b>	<b>22,667,023</b>	<b>7,298,211</b>
<b>Net assets</b>	<b>\$947,338,721</b>	<b>\$1,635,599,803</b>
<b>Net assets consist of</b>		
Paid in capital	\$919,160,721	\$992,210,161
Undistributed net investment loss	(37,364,973)	(32,061,601)
Accumulated net realized gain on investments and foreign currency related transactions	379,496,888	441,307,277
Net unrealized (depreciation)/appreciation on investments and foreign currency related transactions	(313,953,915)	234,143,966
<b>Net assets</b>	<b>\$947,338,721</b>	<b>\$1,635,599,803</b>

The accompanying notes are an integral part of these financial statements

GRANAHAN FUNDS PLC

**STATEMENT OF OPERATIONS (UNAUDITED)**  
**For the financial period ended June 30, 2022**

	<b>Granahan US Focused Growth Fund</b>	<b>Granahan US Focused Growth Fund</b>
	<b>Financial period ended</b>	<b>Financial period ended</b>
	<b>June 30, 2022</b>	<b>June 30, 2021</b>
<b>Investment income</b>		\$394,878
Dividends	\$174,467	
Dividend withholding tax	(52,340)	(113,209)
Other income	588,713	7,768
<b>Total investment income</b>	<b>710,840</b>	<b>289,437</b>
<b>Expenses (See note 5)</b>		
Investment Management fees	2,781,874	3,921,744
Administration fees	184,585	183,624
Manager fees	68,494	100,574
Audit fees	6,539	8,129
Depository fees	108,263	129,398
Directors' fees	20,448	25,423
Legal fees	34,179	42,494
Performance fees (See note 5)	-	1,152,361
Transaction costs (See note 7)	410,768	256,360
Other expenses (See note 8)	33,850	54,192
<b>Total expenses</b>	<b>3,649,000</b>	<b>5,874,299</b>
Expense reimbursement from Investment Manager (See note 5)	(278,502)	(310,526)
Net expenses	3,370,498	5,563,773
<b>Net investment loss</b>	<b>(2,659,658)</b>	<b>(5,274,336)</b>
<b>Realized and unrealized (loss)/gain on investments</b>		
Net realized (loss)/gain on:		
Investments	(35,797,565)	105,497,876
Foreign currency related transactions	(268,062)	(292,222)
Net change in unrealized (depreciation)/appreciation on:		1,041,363
Investments	(303,474,016)	
<b>Net realized and unrealized (loss)/gain on investments</b>	<b>(339,539,643)</b>	<b>106,247,017</b>
<b>Net (decrease)/increase in net assets resulting from operations</b>	<b>\$(342,199,301)</b>	<b>\$100,972,681</b>

For the financial period ended June 30, 2022, there are no other gains or losses other than those included in the Statement of Operations. All income arises from continuing operations.

The accompanying notes are an integral part of these financial statements.

GRANAHAN FUNDS PLC

**STATEMENT OF OPERATIONS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

	<b>Granahan US Small Cap Discoveries Fund Financial period ended June 30, 2022</b>	<b>Granahan US Small Cap Discoveries Fund Financial period ended June 30, 2021</b>
<b>Investment income</b>		
Dividends	\$54,253	\$75,519
Dividend withholding tax	(12,312)	(16,221)
Other income	1,762	1,149
<b>Total investment income</b>	<b>43,703</b>	<b>60,447</b>
<b>Expenses (See note 5)</b>		
Investment Management fees	120,097	140,637
Administration fees	22,195	27,416
Manager fees	3,626	4,209
Audit fees	346	341
Depository fees	11,533	18,008
Directors' fees	1,083	1,065
Legal fees	1,810	1,780
Transaction costs (See note 7)	65,065	30,636
Other expenses (See note 8)	2,128	8,511
<b>Total expenses</b>	<b>227,883</b>	<b>232,603</b>
Expense reimbursement from Investment Manager (See note 5)	(16,376)	(35,159)
Net expenses	211,507	197,444
<b>Net investment loss</b>	<b>(167,804)</b>	<b>(136,997)</b>
<b>Realized and unrealized (loss)/gain on investments</b>		
Net realized (loss)/gain on:		
Investments	(2,464,240)	5,418,370
Foreign currency related transactions	217	(44)
Net change in unrealized (depreciation)/appreciation on:		
Investments	(13,279,096)	2,689,952
<b>Net realized and unrealized (loss)/gain on investments</b>	<b>(15,743,119)</b>	<b>8,108,278</b>
<b>Net (decrease)/increase in net assets resulting from operations</b>	<b>\$(15,910,923)</b>	<b>\$7,971,281</b>

For the financial period ended June 30, 2022, there are no other gains or losses other than those included in the Statement of Operations. All income arises from continuing operations.

The accompanying notes are an integral part of these financial statements.

GRANAHAN FUNDS PLC

**STATEMENT OF OPERATIONS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

	<b>Granahan US SMID Select Fund</b>	<b>Granahan US SMID Select Fund</b>
	<b>Financial period ended June 30, 2022</b>	<b>Financial period ended June 30, 2021</b>
<b>Investment income</b>		
Dividends	\$305,638	\$371,625
Dividend withholding tax	(72,728)	(93,329)
Other income	11,092	2,051
<b>Total investment income</b>	<b>244,002</b>	<b>280,347</b>
<b>Expenses (See note 5)</b>		
Investment Manager fees	2,241,995	2,492,769
Administration fees	119,133	75,493
Manager fees	52,686	58,055
Audit fees	5,037	4,679
Depository fees	89,790	92,591
Directors' fees	15,753	14,633
Legal fees	26,332	24,459
Transaction costs (See note 7)	460,466	421,824
Other expenses (See note 8)	21,503	24,981
<b>Total expenses</b>	<b>3,032,695</b>	<b>3,209,484</b>
Expense reimbursement from Investment Manager (See note 5)	(312,783)	(280,013)
Net expenses	2,719,912	2,929,471
<b>Net investment loss</b>	<b>(2,475,910)</b>	<b>(2,649,124)</b>
<b>Realized and unrealized (loss)/gain on investments</b>		
Net realized (loss)/gain on:		
Investments	(22,976,170)	68,591,040
Foreign currency related transactions	(304,569)	(352,168)
Net change in unrealized (depreciation)/appreciation on:		
Investments	(231,344,171)	33,168,489
Foreign currency related transactions	(598)	-
<b>Net realized and unrealized (loss)/gain on investments</b>	<b>(254,625,508)</b>	<b>101,407,361</b>
<b>Net (decrease)/increase in net assets resulting from operations</b>	<b>\$(257,101,418)</b>	<b>\$98,758,237</b>

For the financial period ended June 30, 2022, there are no other gains or losses other than those included in the Statement of Operations. All income arises from continuing operations.

The accompanying notes are an integral part of these financial statements.



GRANAHAN FUNDS PLC

**STATEMENT OF OPERATIONS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

	<b>Total</b>	<b>Total</b>
	<b>Financial period ended</b>	<b>Financial period ended</b>
	<b>June 30, 2022</b>	<b>June 30, 2021</b>
<b>Investment income</b>		
Dividends	\$534,358	\$842,022
Dividend withholding tax	(137,380)	(222,759)
Other income	601,567	10,968
<b>Total investment income</b>	<b>998,545</b>	<b>630,231</b>
<b>Expenses (See note 5)</b>		
Investment Management fees	5,143,966	6,555,150
Administration fees	325,913	286,533
Manager fees	124,806	162,838
Audit fees	11,922	13,149
Depository fees	209,586	239,997
Directors' fees	37,284	41,121
Legal fees	62,321	68,733
Performance fees (See note 5)	-	1,152,361
Transaction costs (See note 7)	936,299	708,820
Other expenses (See note 8)	57,481	87,684
<b>Total expenses</b>	<b>6,909,578</b>	<b>9,316,386</b>
Expense reimbursement from Investment Manager (See note 5)	(607,661)	(625,698)
Net expenses	6,301,917	8,690,688
<b>Net investment loss</b>	<b>(5,303,372)</b>	<b>(8,060,457)</b>
<b>Realized and unrealized (loss)/gain on investments</b>		
Net realized (loss)/gain on:		
Investments	(61,237,975)	179,507,286
Foreign currency related transactions	(572,414)	(644,434)
Net change in unrealized (depreciation)/appreciation on:		
Investments	(548,097,283)	36,899,804
Foreign currency related transactions	(598)	-
<b>Net realized and unrealized (loss)/gain on investments</b>	<b>(609,908,270)</b>	<b>215,762,656</b>
<b>Net (decrease)/increase in net assets resulting from operations</b>	<b>\$(615,211,642)</b>	<b>\$207,702,199</b>

For the financial period ended June 30, 2022, there are no other gains or losses other than those included in the Statement of Operations. All income arises from continuing operations.

The accompanying notes are an integral part of these financial statements.

GRANAHAN FUNDS PLC

**STATEMENT OF CHANGES IN NET ASSETS (UNAUDITED)**  
**For the financial period ended June 30, 2022**

	<b>Granahan US Focused Growth Fund Financial period ended June 30, 2022</b>	<b>Granahan US Focused Growth Fund Financial period ended June 30, 2021</b>
<b>Operations</b>		
Net investment loss	\$(2,659,658)	\$(5,274,336)
Net realized (loss)/gain on investments and foreign currency related transactions	(36,065,627)	105,205,654
Net change in unrealized (depreciation)/appreciation on investments and foreign currency transactions	(303,474,016)	1,041,363
<b>Net (decrease)/increase in net assets resulting from operations</b>	<b>(342,199,301)</b>	<b>100,972,681</b>
<b>Capital Share Transactions (See note 3)</b>		
Proceeds from shares sold		
Class A GBP Accumulating	3,147,325	8,994,556
Class A USD Accumulating	17,022,138	105,914,993
Class A USD Distributing	378,005	6,031,664
Class F EUR Accumulating	445,280	19,281,176
Class I EUR Accumulating	3,982,581	78,840,396
Class I GBP Accumulating	12,127,574	28,118,210
Class I USD Accumulating	98,361,261	116,902,853
Class I USD Distributing	19,416,130	40,904,660
Cost of shares redeemed		
Class A GBP Accumulating	(5,433,879)	(4,307,292)
Class A USD Accumulating	(34,722,080)	(109,896,813)
Class A USD Distributing	(1,237,323)	(14,419,252)
Class F EUR Accumulating	(1,424,740)	(16,125,401)
Class F GBP Accumulating	(83,642)	-
Class I EUR Accumulating	(49,860,968)	(47,391)
Class I GBP Accumulating	(10,551,815)	(5,992,629)
Class I USD Accumulating	(39,707,852)	(88,602,519)
Class I USD Distributing	(24,442,690)	(38,238,551)
Class P USD Accumulating*	(54,612,531)	(16,794,701)
Class P1 USD Accumulating	(35,289,000)	-

\*This share class was terminated on April 20, 2022.

The accompanying notes are an integral part of these financial statements.

**STATEMENT OF CHANGES IN NET ASSETS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

	<b>Granahan US Focused Growth Fund Financial period ended June 30, 2022</b>	<b>Granahan US Focused Growth Fund Financial period ended June 30, 2021</b>
<b>Net (decrease)/increase in net assets from capital share transactions</b>	<b>\$(102,486,226)</b>	<b>\$110,563,959</b>
<b>Distributions to Shareholders</b>		
Total distributions	-	-
<b>Total (decrease)/increase in net assets</b>	<b>\$(444,685,527)</b>	<b>\$211,536,640</b>
<b>Net assets beginning of financial period</b>	<b>\$952,988,524</b>	<b>\$859,036,580</b>
<b>Net assets end of financial period</b>	<b>\$508,302,997</b>	<b>\$1,070,573,220</b>

The accompanying notes are an integral part of these financial statements.

GRANAHAN FUNDS PLC

**STATEMENT OF CHANGES IN NET ASSETS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

	Granahan US Small Cap Discoveries Fund Financial period ended June 30, 2022	Granahan US Small Cap Discoveries Fund Financial period ended June 30, 2021
<b>Operations</b>		
Net investment loss	\$(167,804)	\$(136,997)
Net realized (loss)/gain on investments and foreign currency related transactions	(2,464,023)	5,418,326
Net change in unrealized (depreciation)/appreciation on investments and foreign currency transactions	(13,279,096)	2,689,952
<b>Net (decrease)/increase in net assets resulting from operations</b>	<b>(15,910,923)</b>	<b>7,971,281</b>
<b>Capital Share Transactions (See note 3)</b>		
Proceeds from shares sold		
Class Founder GBP Accumulating	-	11,624
Class Founder USD Accumulating	897,825	10,443,872
Cost of shares redeemed		
Class Founder GBP Accumulating	(6,714)	-
Class Founder USD Accumulating	(1,261,326)	(6,488,016)
<b>Net (decrease)/increase in net assets from capital share transactions</b>	<b>\$(370,215)</b>	<b>\$3,967,480</b>
<b>Distributions to Shareholders</b>		
Total distributions	-	-
<b>Total (decrease)/increase in net assets</b>	<b>\$(16,281,138)</b>	<b>\$11,938,761</b>
<b>Net assets beginning of financial period</b>	<b>\$45,175,447</b>	<b>\$36,365,361</b>
<b>Net assets end of financial period</b>	<b>\$28,894,309</b>	<b>\$48,304,122</b>

The accompanying notes are an integral part of these financial statements.

**GRANAHAN FUNDS PLC**

**STATEMENT OF CHANGES IN NET ASSETS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

	<b>Granahan US SMID Select Fund Financial period ended June 30, 2022</b>	<b>Granahan US SMID Select Fund Financial period ended June 30, 2021</b>
<b>Operations</b>		
Net investment loss	\$(2,475,910)	\$(2,649,124)
Net realized (loss)/gain on investments and foreign currency related transactions	(23,280,739)	68,238,872
Net change in unrealized (depreciation)/appreciation on investments and foreign currency transactions	(231,344,769)	33,168,489
<b>Net (decrease)/increase in net assets resulting from operations</b>	<b>(257,101,418)</b>	<b>98,758,237</b>
<b>Capital Share Transactions (See note 3)</b>		
Proceeds from shares sold		
Class A GBP Accumulating	63,509	4,252,357
Class A GBP Distributing	-	103,001
Class A USD Accumulating	5,301,252	20,215,902
Class I GBP Accumulating	64,425,661	51,879,623
Class I GBP Distributing	16,481,954	51,400,528
Class I USD Accumulating	8,831,123	7,831,183
Class I USD Distributing	263,147	11,107,108
Cost of shares redeemed		
Class A GBP Accumulating	(2,691,988)	(758,383)
Class A USD Accumulating	(5,812,003)	(2,400,951)
Class I GBP Accumulating	(26,961,011)	(33,829,509)
Class I GBP Distributing	(16,699,746)	(4,104,145)
Class I USD Accumulating	(11,978,667)	(999,200)
Class I USD Distributing	(1,416,230)	(45,863)
<b>Net increase in net assets from capital share transactions</b>	<b>\$29,807,001</b>	<b>\$104,651,651</b>
<b>Distributions to Shareholders</b>		
Total distributions	-	-
<b>Total (decrease)/increase in net assets</b>	<b>\$(227,294,417)</b>	<b>\$203,409,888</b>
<b>Net assets beginning of financial period</b>	<b>\$637,435,832</b>	<b>\$428,992,618</b>
<b>Net assets end of financial period</b>	<b>\$410,141,415</b>	<b>\$632,402,506</b>

The accompanying notes are an integral part of these financial statements.

GRANAHAN FUNDS PLC

**STATEMENT OF CHANGES IN NET ASSETS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

	Total Financial period ended June 30, 2022	Total Financial period ended June 30, 2021
<b>Operations</b>		
Net investment loss	\$(5,303,372)	\$(8,060,457)
Net realized (loss)/gain on investments and foreign currency related transactions	(61,810,389)	178,862,852
Net change in unrealized (depreciation)/appreciation on investments and foreign currency transactions	(548,097,881)	36,899,804
<b>Net (decrease)/increase in net assets resulting from operations</b>	<b>\$(615,211,642)</b>	<b>\$207,702,199</b>
<b>Capital Share Transactions (See note 3)</b>		
Proceeds from shares sold	251,144,765	562,233,706
Cost of shares redeemed	(324,194,205)	(343,050,616)
<b>Net (decrease)/increase in net assets from capital share</b>	<b>\$(73,049,440)</b>	<b>\$219,183,090</b>
<b>Distributions to Shareholders</b>		
Total distributions	-	-
<b>Total (decrease)/increase in net assets</b>	<b>\$(688,261,082)</b>	<b>\$426,885,289</b>
<b>Net assets beginning of financial period</b>	<b>\$1,635,599,803</b>	<b>\$1,324,394,559</b>
<b>Net assets end of financial period</b>	<b>\$947,338,721</b>	<b>\$1,751,279,848</b>

The accompanying notes are an integral part of these financial statements

**FINANCIAL HIGHLIGHTS (UNAUDITED)**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US Focused Growth Fund**

<b>Class A EUR Accumulating</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	€9.28	€10.00
<b>Income from Investment Operations</b>		
Net investment loss	(0.04)	(0.05)
Net realized and unrealized loss on investments	(3.18)	(0.67)
Total from investment operations	<u>€(3.22)</u>	<u>€(0.72)</u>
<b>Net Asset Value – End of Financial period</b>	<u>€6.06</u>	<u>€9.28</u>
<b>Total Return</b>	(34.70)%	(7.20)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	€133	€204
Ratio of expenses to average net assets:		
After expense reimbursement	1.11%	1.10%
Before expense reimbursement	1.13%	1.15%
Ratio of net investment income to average net assets:		
After expense reimbursement	(1.09)%	(1.07)%
Before expense reimbursement	(1.11)%	(1.12)%
 <b>Class A GBP Accumulating</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	£16.77	£16.77
<b>Income from Investment Operations</b>		
Net investment loss	(0.09)	(0.26)
Net realized and unrealized gain on investments	(5.47)	0.25
Total from investment operations	<u>£(5.56)</u>	<u>£(0.01)</u>
<b>Net Asset Value – End of Financial period</b>	<u>£11.21</u>	<u>£16.76</u>
<b>Total Return</b>	(33.15)%	(0.06)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	£12,046	£20,321
Ratio of expenses to average net assets:		
After expense reimbursement	1.11%	1.06%
Before expense reimbursement	1.13%	1.11%
Ratio of net investment income to average net assets:		
After expense reimbursement	(1.09)%	(1.04)%
Before expense reimbursement	(1.11)%	(1.08)%

The accompanying notes are an integral part of these financial statements.

GRANAHAN FUNDS PLC

**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US Focused Growth Fund**

<b>Class A USD Accumulating</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$528.75	\$534.53
<b>Income from Investment Operations</b>		
Net investment loss	(2.17)	(6.06)
Net realized and unrealized (loss)/gain on investments	(208.72)	0.28
Total from investment operations	<u>\$(210.89)</u>	<u>\$(5.78)</u>
<b>Net Asset Value – End of Financial period</b>	<u>\$317.86</u>	<u>\$528.75</u>
<b>Total Return</b>	(39.88)%	(1.08)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$82,163	\$158,500
Ratio of expenses to average net assets:		
After expense reimbursement	1.11%	1.08%
Before expense reimbursement	1.13%	1.10%
Ratio of net investment income to average net assets:		
After expense reimbursement	(1.09)%	(1.05)%
Before expense reimbursement	(1.11)%	(1.08)%
 <b>Class A USD Distributing</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$210.11	\$212.41
<b>Income from Investment Operations</b>		
Net investment loss	(0.87)	(2.40)
Net realized and unrealized (loss)/gain on investments	(82.93)	0.10
Total from investment operations	<u>\$(83.80)</u>	<u>\$(2.30)</u>
<b>Net Asset Value – End of Financial period</b>	<u>\$126.31</u>	<u>\$210.11</u>
<b>Total Return</b>	(39.88)%	(1.08)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$5,225	\$9,924
Ratio of expenses to average net assets:		
After expense reimbursement	1.11%	1.07%
Before expense reimbursement	1.13%	1.10%
Ratio of net investment income to average net assets:		
After expense reimbursement	(1.09)%	(1.05)%
Before expense reimbursement	(1.11)%	(1.08)%

The accompanying notes are an integral part of these financial statements.



**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US Focused Growth Fund**

<b>Class F EUR Accumulating</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	€19.21	€18.12
<b>Income from Investment Operations</b>		
Net investment loss	(0.11)	(0.30)
Net realized and unrealized (loss)/gain on investments	(6.57)	1.39
Total from investment operations	<u>€(6.68)</u>	<u>€1.09</u>
<b>Net Asset Value – End of Financial period</b>	<u>€12.53</u>	<u>€19.21</u>
<b>Total Return</b>	(34.77)%	6.02%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	€1,274	€3,006
Ratio of expenses to average net assets:		
After expense reimbursement	1.38%	1.33%
Before expense reimbursement	1.38%	1.35%
Ratio of net investment income to average net assets:		
After expense reimbursement	(1.35)%	(1.29)%
Before expense reimbursement	(1.35)%	(1.31)%
 <b>Class F GBP Accumulating</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	£12.55	£12.61
<b>Income from Investment Operations</b>		
Net investment loss	(0.09)	(0.26)
Net realized and unrealized (loss)/gain on investments	(4.08)	0.20
Total from investment operations	<u>£(4.17)</u>	<u>£(0.06)</u>
<b>Net Asset Value – End of Financial period</b>	<u>£8.38</u>	<u>£12.55</u>
<b>Total Return</b>	(33.23)%	(0.48)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	£35	£127
Ratio of expenses to average net assets:		
After expense reimbursement	1.35%	1.40%
Before expense reimbursement	1.38%	1.35%
Ratio of net investment income to average net assets:		
After expense reimbursement	(1.35)%	(1.38)%
Before expense reimbursement	(1.35)%	(1.33)%

The accompanying notes are an integral part of these financial statements.

**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US Focused Growth Fund**

Class I EUR Accumulating	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	€9.93	€10.00
<b>Income from Investment Operations</b>		
Net investment loss	(0.04)	(0.08)
Net realized and unrealized (loss)/gain on investments	(3.40)	0.01
Total from investment operations	€(3.44)	€(0.07)
<b>Net Asset Value – End of Financial period</b>	€6.49	€9.93
<b>Total Return</b>	(34.64)%	(0.70)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	€12,206	€66,981
Ratio of expenses to average net assets:		
After expense reimbursement	0.93%	0.94%
Before expense reimbursement	1.07%	1.07%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.93)%	(0.92)%
Before expense reimbursement	(1.05)%	(1.04)%
 <b>Class I GBP Accumulating</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	£15.97	£15.95
<b>Income from Investment Operations</b>		
Net investment loss	(0.07)	(0.21)
Net realized and unrealized (loss)/gain on investments	(5.21)	0.23
Total from investment operations	£(5.28)	£0.02
<b>Net Asset Value – End of Financial period</b>	£10.69	£15.97
<b>Total Return</b>	(33.06)%	0.13%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	£22,143	£33,061
Ratio of expenses to average net assets:		
After expense reimbursement	0.93%	0.89%
Before expense reimbursement	1.07%	1.01%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.91)%	(0.87)%
Before expense reimbursement	(1.05)%	(0.99)%

The accompanying notes are an integral part of these financial statements.

**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US Focused Growth Fund**

<b>Class I USD Accumulating</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$24.16	\$24.39
<b>Income from Investment Operations</b>		
Net investment loss	(0.34)	(0.37)
Net realized and unrealized (loss)/gain on investments	(9.28)	0.14
Total from investment operations	<u>\$(9.62)</u>	<u>\$(0.23)</u>
<b>Net Asset Value – End of Financial period</b>	<u>\$14.54</u>	<u>\$24.16</u>
<b>Total Return</b>	(39.82)%	(0.94)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$210,143	\$248,738
Ratio of expenses to average net assets:		
After expense reimbursement	0.93%	0.94%
Before expense reimbursement	1.07%	1.06%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.91)%	(0.91)%
Before expense reimbursement	(1.05)%	(1.03)%
 <b>Class I USD Distributing</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$24.15	\$24.38
<b>Income from Investment Operations</b>		
Net investment loss	(0.08)	(0.24)
Net realized and unrealized (loss)/gain on investments	(9.54)	0.01
Total from investment operations	<u>\$(9.62)</u>	<u>\$(0.23)</u>
<b>Net Asset Value – End of Financial period</b>	<u>\$14.53</u>	<u>\$24.15</u>
<b>Total Return</b>	(39.83)%	(0.94)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$98,871	\$176,140
Ratio of expenses to average net assets:		
After expense reimbursement	0.93%	0.94%
Before expense reimbursement	1.07%	1.06%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.91)%	(0.91)%
Before expense reimbursement	(1.05)%	(1.03)%

The accompanying notes are an integral part of these financial statements.

**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US Focused Growth Fund**

<b>Class P USD Accumulating*</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$23.03	\$23.00
<b>Income from Investment Operations</b>		
Net investment loss	(0.05)	(0.11)
Net realized and unrealized (loss)/gain on investments	(4.99)	0.14
Total from investment operations	\$(5.04)	\$0.03
<b>Net Asset Value – End of Financial period</b>	\$17.99	\$23.03
<b>Total Return</b>	(21.88)%	0.13%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$13,453	\$68,868
Ratio of expenses to average net assets:		
After expense reimbursement	0.51%	0.47%
Before expense reimbursement	0.51%	0.50%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.51)%	(0.45)%
Before expense reimbursement	(0.51)%	(0.48)%
<b>Class P1 USD Accumulating</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$13.91	\$13.88
<b>Income from Investment Operations</b>		
Net investment loss	(0.03)	(0.07)
Net realized and unrealized (loss)/gain on investments	(5.47)	0.10
Total from investment operations	\$(5.50)	\$0.03
<b>Net Asset Value – End of Financial period</b>	\$8.41	\$13.91
<b>Total Return</b>	(39.54)%	0.22%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$55,979	\$138,491
Ratio of expenses to average net assets:		
After expense reimbursement	0.51%	0.47%
Before expense reimbursement	0.53%	0.50%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.49)%	(0.45)%
Before expense reimbursement	(0.51)%	(0.48)%

\*This share class was terminated on April 20, 2022.

The accompanying notes are an integral part of these financial statements.

**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US Small Cap Discoveries Fund**

<b>Class Founder GBP Accumulating</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	£17.11	£16.35
<b>Income from Investment Operations</b>		
Net investment loss	(0.05)	(0.13)
Net realized and unrealized (loss)/gain on investments	(4.78)	0.89
Total from investment operations	<u>£(4.83)</u>	<u>£0.76</u>
<b>Net Asset Value – End of Financial period</b>	<u>£12.28</u>	<u>£17.11</u>
<b>Total Return</b>	(28.23)%	4.65%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	£13	£25
Ratio of expenses to average net assets:		
After expense reimbursement	0.81%	0.77%
Before expense reimbursement	0.91%	0.93%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.61)%	(0.50)%
Before expense reimbursement	(0.69)%	(0.66)%
 <b>Class Founder USD Accumulating</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$21.21	\$20.47
<b>Income from Investment Operations</b>		
Net investment loss	(0.05)	(0.12)
Net realized and unrealized (loss)/gain on investments	(7.47)	0.86
Total from investment operations	<u>\$(7.52)</u>	<u>\$0.74</u>
<b>Net Asset Value – End of Financial period</b>	<u>\$13.69</u>	<u>\$21.21</u>
<b>Total Return</b>	(35.45)%	3.62%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$28,879	\$45,142
Ratio of expenses to average net assets:		
After expense reimbursement	0.83%	0.77%
Before expense reimbursement	0.93%	0.93%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.61)%	(0.50)%
Before expense reimbursement	(0.71)%	(0.66)%

The accompanying notes are an integral part of these financial statements.

**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US SMID Select Fund**

<b>Class A GBP Accumulating</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	£103.24	£100.00
<b>Income from Investment Operations</b>		
Net investment loss	(0.51)	(1.29)
Net realized and unrealized (loss)/gain on investments	(33.43)	4.53
Total from investment operations	£(33.94)	£3.24
<b>Net Asset Value – End of Financial period</b>	£69.30	£103.24
<b>Total Return</b>	(32.87)%	3.24%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	£421	£3,374
Ratio of expenses to average net assets:		
After expense reimbursement	1.03%	1.03%
Before expense reimbursement	1.03%	1.03%
Ratio of net investment income to average net assets:		
After expense reimbursement		(0.90)%
Before expense reimbursement	-0.95%	(0.90)%
 <b>Class A GBP Distributing</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	£99.21	£100.00
<b>Income from Investment Operations</b>		
Net investment loss	(0.47)	(1.19)
Net realized and unrealized (loss)/gain on investments	(32.14)	0.40
Total from investment operations	£(32.61)	£(0.79)
<b>Net Asset Value – End of Financial period</b>	£66.60	£99.21
<b>Total Return</b>	(32.87)%	(0.79)%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	£50	£74
Ratio of expenses to average net assets:		
After expense reimbursement	1.03%	1.00%
Before expense reimbursement	1.03%	1.02%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.93)%	(0.90)%
Before expense reimbursement	(0.93)%	(0.92)%

The accompanying notes are an integral part of these financial statements.

**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US SMID Select Fund**

<b>Class A USD Accumulating</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$102.91	\$100.00
<b>Income from Investment Operations</b>		
Net investment loss	(0.36)	(0.96)
Net realized and unrealized (loss)/gain on investments	(40.43)	3.87
Total from investment operations	<u>\$(40.79)</u>	<u>\$2.91</u>
<b>Net Asset Value – End of Financial period</b>	<u>\$62.12</u>	<u>\$102.91</u>
<b>Total Return</b>	(39.64)%	2.91%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$10,771	\$18,071
Ratio of expenses to average net assets:		
After expense reimbursement	1.03%	1.01%
Before expense reimbursement	1.03%	1.04%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.93)%	(0.91)%
Before expense reimbursement	(0.95)%	(0.94)%
 <b>Class I GBP Accumulating</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	£222.78	£200.65
<b>Income from Investment Operations</b>		
Net investment loss	(0.92)	(2.60)
Net realized and unrealized (loss)/gain on investments	(72.23)	24.73
Total from investment operations	<u>£(73.15)</u>	<u>£22.13</u>
<b>Net Asset Value – End of Financial period</b>	<u>£149.63</u>	<u>£222.78</u>
<b>Total Return</b>	(32.84)%	11.03%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	£260,453	£349,402
Ratio of expenses to average net assets:		
After expense reimbursement	0.91%	0.91%
Before expense reimbursement	1.03%	1.02%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.81)%	(0.82)%
Before expense reimbursement	(0.93)%	(0.93)%

The accompanying notes are an integral part of these financial statements.

**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US SMID Select Fund**

<b>Class I GBP Distributing</b>	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	£123.36	£111.12
<b>Income from Investment Operations</b>		
Net investment loss	(0.51)	(1.44)
Net realized and unrealized (loss)/gain on investments	(39.99)	13.68
Total from investment operations	£(40.50)	£12.24
<b>Net Asset Value – End of Financial period</b>	£82.86	£123.36
<b>Total Return</b>	(32.83)%	11.02%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	£44,283	£66,856
Ratio of expenses to average net assets:		
After expense reimbursement	0.91%	0.91%
Before expense reimbursement	1.03%	1.03%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.81)%	(0.81)%
Before expense reimbursement	(0.93)%	(0.93)%
 <b>Class I USD Accumulating</b>	 <b>June 2022</b>	 <b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$119.95	\$109.16
<b>Income from Investment Operations</b>		
Net investment loss	(0.37)	(1.04)
Net realized and unrealized (loss)/gain on investments	(47.12)	11.83
Total from investment operations	\$(47.49)	\$10.79
<b>Net Asset Value – End of Financial period</b>	\$72.46	\$119.95
<b>Total Return</b>	(39.59)%	9.88%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$21,277	\$38,705
Ratio of expenses to average net assets:		
After expense reimbursement	0.91%	0.91%
Before expense reimbursement	1.03%	1.03%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.81)%	(0.82)%
Before expense reimbursement	(0.95)%	(0.93)%

The accompanying notes are an integral part of these financial statements.



**FINANCIAL HIGHLIGHTS (UNAUDITED) – continued**  
**For a share outstanding throughout the financial period ended June 30, 2022 and**  
**comparatives for the financial year ended December 31, 2021**

**Granahan US SMID Select Fund**

Class I USD Distributing	<b>June 2022</b>	<b>December 2021</b>
<b>Net Asset Value – Beginning of Financial period</b>	\$120.05	\$109.25
<b>Income from Investment Operations</b>		
Net investment loss	(0.37)	(1.03)
Net realized and unrealized (loss)/gain on investments	(47.16)	11.83
Total from investment operations	\$(47.53)	\$10.80
<b>Net Asset Value – End of Financial period</b>	\$72.52	\$120.05
<b>Total Return</b>	(39.59)%	9.89%
<b>Ratios and Supplemental Data</b>		
Net assets, end of financial period (thousands)	\$6,568	\$12,575
Ratio of expenses to average net assets:		
After expense reimbursement	0.91%	0.91%
Before expense reimbursement	1.03%	1.02%
Ratio of net investment income to average net assets:		
After expense reimbursement	(0.81)%	(0.81)%
Before expense reimbursement	(0.95)%	(0.93)%

The accompanying notes are an integral part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)**  
**For the financial period ended June 30, 2022**

## **1. Organization**

The Company is an open-ended umbrella investment company with variable capital and segregated liability between its sub-funds and is organised under the laws of Ireland as a public limited company pursuant to the Companies Act 2014 (as amended). The Company is authorised by the Central Bank of Ireland pursuant to the UCITS Regulations and the Central Bank UCITS Regulations.

The Company was incorporated on October 3, 2013 under registration number 533587.

The Directors have established three sub-funds (the “Funds”, each a “Fund”):

- Granahan US Focused Growth Fund
- Granahan US Small Cap Discoveries Fund
- Granahan US SMID Select Fund

Granahan US Focused Growth Fund commenced operations on April 11, 2014, Granahan US Small Cap Discoveries Fund commenced operations on June 30, 2017 and Granahan US SMID Select Fund commenced operations on January 23, 2020.

The investment objective of Granahan US Focused Growth Fund is to seek capital appreciation through investment in a limited number of small, dynamic and sustainable growth companies and to outperform the Russell 2000 Growth Index.

The investment objective of Granahan US Small Cap Discoveries Fund is to seek capital appreciation through investment in small, dynamic and emerging growth companies.

The investment objective of Granahan US SMID Select Fund is to seek capital appreciation through investment in small and mid-capitalisation, dynamic and emerging growth companies.

A separate portfolio of assets is maintained for each Fund and invests in accordance with its investment objectives and policies.

## **2. Significant Accounting Policies**

The following is a summary of significant accounting policies consistently followed by the Company in the preparation of its financial statements. These policies are in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”).

- a) Valuation of Securities – Securities that are primarily traded on an official stock exchange are valued at the last traded price (or if no last traded price is available the latest mid-market price) on the exchange on which they are primarily traded on the day of valuation. Any securities or other assets for which market quotations are not readily available are valued at such value as shall be certified with care and good faith as the probable realization value by a competent person, appointed for such purpose by the Directors in consultation with the Investment Manager and approved by the Depositary. The values for foreign securities are reported in local currency and converted to US Dollar using currency exchange rates at the time of valuation. Exchange rates are provided daily by recognized independent pricing agents.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**2. Significant Accounting Policies (continued)**

- b) Distributions to Shareholders – For all accumulating classes of shares, the Directors intend to accumulate and to automatically reinvest all earnings, dividends and other distributions of whatever kind pursuant to the investment objectives and policies of the relevant fund for the benefit of Shareholders in the relevant fund. The Directors intend to declare a quarterly dividend in respect of the distributing classes for the net income earned in the period (interest plus dividends, less fund expenses). To date, none of the distributing share classes have accumulated net income in any period. Any change to the distribution policy of a fund will be notified in advance to Shareholders and will be noted in an addendum or a revision to the Prospectus.
- c) Basis of preparation – The accompanying financial statements have been prepared in conformity with US GAAP. The accompanying financial statements have been prepared under a going concern basis.
- d) Use of Estimates – The preparation of the financial statements in conformity with US GAAP requires Directors to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Directors believe that the estimates utilized in preparing its financial statements are reasonable and prudent; however, actual results could differ from these estimates.
- e) Guarantees and Indemnification – In the normal course of business, the Company enters into contracts with service providers that contain general indemnification clauses. The Company’s maximum exposure under these arrangements is unknown as this would involve future claims that may be made against the Company that have not yet occurred. Based on experience, however, the Company expects the risk of loss to be remote.
- f) Other – Investment and Shareholder transactions are recorded on trade date. The Company determines the gain or loss realized from the investment transactions by comparing the original cost of the security sold with the net sales proceeds on a high cost basis. Within the Funds, dividend income is recognized on the ex-dividend date or as soon as information is available and interest income is recognized on an accrual basis.
- g) Functional and Presentation Currency – Items included in the financial statements are measured using the currency of the primary economic environment in which it operates (the “Functional Currency”). The Company’s Functional and presentation currency is US Dollar.
- h) Foreign Exchange Contracts – Transactions during the financial period ended denominated in foreign currencies have been translated at the rates of exchange ruling at the dates of the transactions. Assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the financial period ended end date. The results of operations due to fluctuations in foreign exchange rates on investments from gains or losses arising from the sales or changes in values of the portfolio securities are reported separately. Net realized gains (losses) and net change in unrealized gains (losses) on foreign currency related transactions arise for sales of foreign currencies and currency gains or losses between trade date or ex-date and settlement date on security or dividend transactions.
- i) Transaction Costs – Transaction costs are incremental costs that are directly attributable to the acquisition, issue or disposal of a financial asset or financial liability. An incremental cost is one that would not have been incurred if the entity had not acquired, issued or disposed of the financial instrument. Only transaction costs which are separately identifiable are disclosed. These include transaction costs paid to depositaries and sub-custodians, identifiable brokerage charges and commissions. These requirements are disclosed in note 7.
- j) Expenses - are recognized in the statement of operations on an accruals basis.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**2. Significant Accounting Policies (continued)**

- k) Income - Dividend income is recorded gross of any non-reclaimable withholding taxes suffered on an ex-date. Interest revenue is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount basis.
- l) Recent Accounting Pronouncements – A number of new standards, amendments to standards and interpretations in issue are not yet effective, and have not been applied in preparing these financial statements. None of these are currently expected to have a material effect on the financial statements of the Company.
- m) Recognition/Derecognition – The Company recognizes financial assets or financial liabilities at fair value through profit or loss on the trade date, which is the date on which the Company becomes a party to the contractual provisions of the instrument. Other financial assets and financial liabilities are recognized on the date on which they originated. Financial instruments are measured initially at fair value (transaction price) on trade date with transaction costs recognized immediately in the Statement of Operations directly. In cases where a financial asset or financial liability is not measured at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability are recognized in the Statement of Operations. Subsequent to initial recognition, all instruments classified at fair value through profit or loss are measured at fair value with changes in their fair value recognized in the Statement of Operations. Financial liabilities, other than those at fair value through profit or loss, are measured at amortized cost. Financial liabilities arising from the redeemable shares issued by each Fund are carried at the redemption amount representing the investors' right to a residual interest in each Fund's assets.
- n) Realized gains and losses - The Company records investment transactions on a trade date basis, matching the cost of investments for the purpose of calculating realized gains and losses on an average cost basis. The Company records an unrealized gain or loss to the extent of the difference between the cost and the fair value of the position at any particular point in time. The Company records a realized gain or loss when the position is sold or closed. Realized gains and losses and the movement in unrealized gains and losses are recorded in the Statement of Operations within "Net realized and unrealized gain/ (loss) on investments".
- o) Uncertain tax positions - Accounting Standards Codification 740, Accounting for Uncertainty in Income Taxes ("ASC 740") clarifies the accounting for uncertainty in income taxes recognized in the Company's financial statements. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 requires that the Company determines whether it is more likely than not that a tax position will be sustained upon examination including resolution of any related appeals or litigation processes based on the technical merit position. In evaluating whether a tax position has met the more likely than not recognition threshold, the Company should presume that the position will be examined by the appropriate taxing authority that has full knowledge of all relevant information.

A tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**3. Share Capital**

The authorised share capital of the Company at the date of prospectus (the “Prospectus”) is 500,000,000,000 Shares of no par value and 300,002 redeemable Non-Participating Shares of €1.00 each. Non-Participating Shares do not entitle the holders thereof to any dividend. On a winding up, the Non-Participating Shares entitle the holders thereof to receive the amount paid up thereon but do not otherwise entitle them to participate in the assets of the Company. The Non-Participating Shares are held on behalf of the Granahan Investment Management LLC (“Investment Manager”) and in trust for the benefit of Investment Manager.

The Company intends to provide investors with a choice of funds offering different investment objectives. The Funds aim to achieve their investment objectives while spreading investment risks through investment in transferable securities or liquid financial assets or collective investment schemes or other permitted investments in accordance with the UCITS Regulations.

The Company may compulsorily redeem all of the Shares of the Company if the net asset value of the Company is less than \$30,000,000 or compulsorily redeem all of the Shares of a Fund if the net asset value of that Fund is less than \$30,000,000.

The Company has the right at any time compulsorily to redeem or transfer Shares if in the reasonable belief of the Directors such Shares are acquired or held directly or beneficially by: (i) any person in breach of the law or requirements of any country or governmental authority by virtue of which such person is not qualified to hold Shares including without limitation any exchange control regulations; (ii) by any person who holds less than the minimum holding for the relevant Class (if any) or who does not supply any information or declaration required under the Constitution or the Application Form; (iii) where the continued ownership of such Shares by the Shareholder is deemed to be harmful or injurious to the business or reputation of the Company or a Fund; or (iv) by any person or persons in circumstances (whether directly or indirectly affecting such person or persons and whether taken alone or in conjunction with any other person or persons, connected or not, or any other circumstance appearing to the Directors to be relevant) which in the opinion of the Directors might result in the Company or Fund or the Shareholders as a whole or of any Fund or Class incurring any liability to taxation or suffering legal, pecuniary, regulatory or material administrative disadvantage which the Company or Fund or the Shareholders as a whole or of any Class might not otherwise have incurred or suffered.

None of the active share classes were hedged during the period.

Share transactions for the financial period ended June 30, 2022 and the financial year ended December 31, 2021 were as follows:

	<b>Granahan US Focused Growth Fund</b>	<b>Granahan US Focused Growth Fund</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Class A EUR Accumulating</b>		
Opening number of shares	22,000.00	-
Shares sold	-	22,000.00
Shares redeemed	-	-
Closing number of shares	22,000.00	22,000.00

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**3. Share Capital (continued)**

	<b>Granahan US Focused Growth Fund June 30, 2022</b>	<b>Granahan US Focused Growth Fund December 31, 2021</b>
<b>Class A GBP Accumulating</b>		
Opening number of shares	1,212,791.96	840,909.86
Shares sold	187,288.00	616,946.06
Shares redeemed	(325,034.89)	(245,063.96)
Closing number of shares	1,075,045.07	1,212,791.96
<b>Class A USD Accumulating</b>		
Opening number of shares	299,760.50	275,955.16
Shares sold	43,366.08	259,176.31
Shares redeemed	(84,638.53)	(235,370.97)
Closing number of shares	258,488.05	299,760.50
<b>Class A USD Distributing</b>		
Opening number of shares	47,231.76	82,197.61
Shares sold	2,161.38	31,149.12
Shares redeemed	(8,027.74)	(66,114.97)
Closing number of shares	41,365.40	47,231.76
<b>Class F EUR Accumulating</b>		
Opening number of shares	156,462.89	104,363.53
Shares sold	26,180.00	809,419.49
Shares redeemed	(80,998.43)	(757,320.13)
Closing number of shares	101,644.46	156,462.89
<b>Class F GBP Accumulating</b>		
Opening number of shares	10,133.03	10,133.03
Shares sold	-	-
Shares redeemed	(5,928.34)	-
Closing number of shares	4,204.69	10,133.03
<b>Class I EUR Accumulating</b>		
Opening number of shares	6,748,435.69	-
Shares sold	462,802.88	6,752,435.69
Shares redeemed	(5,330,227.38)	(4,000.00)
Closing number of shares	1,881,011.19	6,748,435.69
<b>Class I GBP Accumulating</b>		
Opening number of shares	2,069,855.25	966,109.05
Shares sold	738,711.63	1,544,400.39
Shares redeemed	(736,697.34)	(440,654.19)
Closing number of shares	2,071,869.54	2,069,855.25

**GRANAHAN FUNDS PLC**

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**3. Share Capital (continued)**

	<b>Granahan US Focused Growth Fund</b>	<b>Granahan US Focused Growth Fund</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Class I USD Accumulating</b>		
Opening number of shares	10,294,662.56	9,556,819.82
Shares sold	6,206,855.91	5,540,688.63
Shares redeemed	(2,047,326.43)	(4,802,845.89)
Closing number of shares	14,454,192.04	10,294,662.56
<b>Class I USD Distributing</b>		
Opening number of shares	7,293,588.69	6,968,875.82
Shares sold	1,005,426.90	2,424,546.26
Shares redeemed	(1,494,601.78)	(2,099,833.39)
Closing number of shares	6,804,413.81	7,293,588.69
<b>Class P USD Accumulating*</b>		
Opening number of shares	2,990,259.04	3,695,893.70
Shares sold	-	-
Shares redeemed	(2,990,259.04)	(705,634.66)
Closing number of shares	-	2,990,259.04
<b>Class P1 USD Accumulating</b>		
Opening number of shares	9,956,225.00	11,756,225.00
Shares sold	-	-
Shares redeemed	(3,300,000.00)	(1,800,000.00)
Closing number of shares	6,656,225.00	9,956,225.00

\*This share class was terminated on April 20, 2022.

	<b>Granahan US Small Cap Discoveries Fund</b>	<b>Granahan US Small Cap Discoveries Fund</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Class Founder GBP Accumulating</b>		
Opening number of shares	1,447.67	1,018.43
Shares sold	-	430.24
Shares redeemed	(429.24)	(1.00)
Closing number of shares	1,018.43	1,447.67
<b>Class Founder USD Accumulating</b>		
Opening number of shares	2,128,499.06	1,775,456.87
Shares sold	51,710.00	769,104.33
Shares redeemed	(70,818.00)	(416,062.14)
Closing number of shares	2,109,391.06	2,128,499.06

**GRANAHAN FUNDS PLC**

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**3. Share Capital (continued)**

	<b>Granahan US SMID Select Fund</b>	<b>Granahan US SMID Select Fund</b>
	<b>June 30, 2022</b>	<b>December 31, 2021</b>
<b>Class A GBP Accumulating</b>		
Opening number of shares	32,684.48	-
Shares sold	595.17	40,680.48
Shares redeemed	(27,207.02)	(7,996.00)
Closing number of shares	6,072.63	32,684.48
<b>Class A GBP Distributing</b>		
Opening number of shares	750.00	-
Shares sold	-	750.00
Shares redeemed	-	-
Closing number of shares	750.00	750.00
<b>Class A USD Accumulating</b>		
Opening number of shares	175,605.42	-
Shares sold	70,054.55	276,883.42
Shares redeemed	(72,280.00)	(101,278.00)
Closing number of shares	173,379.97	175,605.42
<b>Class I GBP Accumulating</b>		
Opening number of shares	1,568,342.47	1,509,144.98
Shares sold	285,647.40	217,668.74
Shares redeemed	(113,396.36)	(158,471.25)
Closing number of shares	1,740,593.51	1,568,342.47
<b>Class I GBP Distributing</b>		
Opening number of shares	541,967.95	44,681.89
Shares sold	124,849.27	536,145.89
Shares redeemed	(132,358.49)	(38,859.83)
Closing number of shares	534,458.73	541,967.95
<b>Class I USD Accumulating</b>		
Opening number of shares	322,673.70	68,792.18
Shares sold	100,337.02	289,989.97
Shares redeemed	(129,363.97)	(36,108.45)
Closing number of shares	293,646.75	322,673.70
<b>Class I USD Distributing</b>		
Opening number of shares	104,751.19	5,451.53
Shares sold	2,787.00	107,341.51
Shares redeemed	(16,959.68)	(8,041.85)
Closing number of shares	90,578.51	104,751.19



**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

#### **4. Taxation**

The Company intends to conduct its affairs so that it is resident in Ireland for tax purposes. On the basis that the Company is Irish tax resident, the Company qualifies as an ‘investment undertaking’, as defined in Section 739B (1) of the Taxes Acts and, consequently, is exempt from Irish corporation tax on its income and gains.

However, tax can arise on the happening of a “chargeable event” in the Company. A chargeable event includes any distribution payments to Shareholders or any encashment, redemption, cancellation or transfer of Shares or appropriation or cancellation of Shares of a Shareholder by the Company for the purposes of meeting the amount of the tax payable on a gain arising on a transfer of an entitlement to a Share. It also includes “Eighth Anniversary Events” regardless of whether the Shares have been encashed, redeemed, cancelled or transferred.

No tax will arise on the Company in respect of chargeable events in respect of a Shareholder who is neither Irish resident nor Irish ordinarily resident at the time of the chargeable event provided that a Relevant Declaration is in place and the Company is not in possession of any information which would reasonably suggest that the information contained therein is not or is no longer materially correct, or provided a written notice of approval from the Revenue Commissioners of Ireland (the “Revenue Commissioners”) to the effect that a Relevant Declaration is deemed to be in place has been provided to the Company and not withdrawn. In the absence of a Relevant Declaration, or a written notice of approval from the Revenue Commissioners, there is a presumption that the investor is Irish resident or Irish ordinarily resident.

A chargeable event does not include:

1. an exchange by a Shareholder, effected by way of an arm’s length bargain of Shares in the Company for other Shares in the Company;
2. any transactions (which might otherwise be a chargeable event) in relation to Shares held in a recognized clearing system as designated by order of the Irish Revenue Commissioners;
3. a transfer by a Shareholder of the entitlement to a Share where the transfer is between spouses and former spouses, subject to certain conditions;
4. an exchange of Shares arising on a qualifying amalgamation or reconstruction of the Company with another investment undertaking (within the meaning of Section 739H or Section 739HA of the Taxes Act);
5. any transaction in relation to, or in respect of, relevant Shares in an investment undertaking which transaction only arises by virtue of a change of court funds manager for that undertaking.

If the Company becomes liable to account for tax where a chargeable event occurs, the Company shall be required to deduct from the payment arising on a chargeable event an amount equal to the appropriate tax and/or where applicable, to appropriate or cancel such number of Shares held by the Shareholder or the beneficial owner of the Shares as are required to meet the amount of tax. The relevant Shareholder shall indemnify and keep the Company indemnified against loss arising to the Company by reason of the Company becoming liable to account for tax on the happening of a chargeable event if no such deduction, appropriation or cancellation has been made.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

## **5. Fees and Expenses**

### **Manager fees**

KBA Consulting Management Limited (the “Manager”) has been appointed as manager for the Company pursuant to the management agreement. Under the terms of the management agreement, the Manager has responsibility for the management and administration of the Company’s affairs, subject to the overall supervision and control of the Directors.

The Manager shall be entitled to receive out of the assets of the relevant Fund, an annual fee, accrued on each Dealing Day and payable quarterly in arrears, at an annual rate of up to and not exceeding 0.01% of the net asset value of the Company subject to a minimum fee of up to €50,000 per annum for the initial Fund and €10,000 for each incremental Fund thereafter. The Manager is also entitled to be reimbursed out of the assets of each Fund for the reasonable out-of-pocket costs and expenses incurred by the Manager in the performance of its duties (plus VAT thereon, if any).

The Manager earned fees of \$124,806 for the financial period ended June 30, 2022 (June 30, 2021: \$162,838). Manager fees payable as at June 30, 2022 amounted to \$56,882 (December 31, 2021: \$93,819).

### **Investment Manager fees**

The Company has appointed the Investment Manager as the discretionary investment manager for the Company pursuant to an investment management agreement. The Investment Manager is a registered investment adviser regulated by the Securities and Exchange Commission (“SEC”).

Under the investment management agreement, the Company will pay to the Investment Manager a maximum fee at an annual rate equal to the percentage of the average daily net asset value of the relevant class of each Fund as set out in the supplement to the Prospectus with the exception of Class X shares which are set out in a separate agreement. The investment management fee shall accrue and be calculated daily and shall be payable monthly in arrears.

In addition, the Investment Manager shall be entitled to be reimbursed its reasonable vouched out-of-pocket expenses.

For Granahan US Focused Growth Fund, the Investment Manager earned fees of \$2,781,874 (June 30, 2021: \$3,921,744) for the financial period ended June 30, 2022 with fees payable as at June 30, 2022 amounting to \$1,268,947 (December 31, 2021: \$2,246,137).

For Granahan US Small Cap Discoveries Fund, the Investment Manager earned fees of \$120,097 (June 30, 2021: \$140,637) for the financial period ended June 30, 2022 with fees payable as at June 30, 2022 amounting to \$54,495 (December 31, 2021: \$83,626).

For Granahan US SMID Select Fund, the Investment Manager earned fees of \$2,241,995 (June 30, 2021: \$2,492,769) For the financial period ended June 30, 2022 with fees payable as at June 30, 2022 amounting to \$1,041,536 (December 31, 2021: \$1,526,182).

For the financial period ended June 30, 2022 the expense reimbursement from the Investment Manager back to the Granahan US Focused Growth Fund in relation to the total expense limitation of 1.35% of the annual net asset value of the funds amounted to \$278,502 (June 30, 2021: \$310,526), and the related receivable amounted to \$131,326 (December 31, 2021: \$343,492).

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**5. Fees and Expenses (continued)**

**Investment Manager fees (continued)**

For the financial period ended June 30, 2022 the expense reimbursement from the Investment Manager back to the Granahan US Small Cap Discoveries Fund in relation to the total expense limitation of 0.85% of the annual net asset value of the funds amounted to \$16,376 (June 30, 2021: \$35,159), and the related receivable amounted to \$6,532 (December 31, 2021: \$41,322).

For the financial period ended June 30, 2022 the expense reimbursement from the Investment Manager back to the Granahan US SMID Select Fund in relation to the total expense limitation of 1.25% of the annual net asset value of the funds amounted to \$312,783 (June 30, 2021: \$280,013), and the related receivable amounted to \$147,476 (December 31, 2021: \$234,162).

**Administration fees**

RBC Investor Services Ireland Limited (the “Administrator”) serves as the Company’s administrator. The Administrator is entitled to receive out of the assets of the Fund an annual fee of up to 2.5 bps of the net asset value of the Fund which will be accrued and payable monthly in arrears, subject to a monthly minimum fee for the Fund of \$2,530 per Fund. The Administrator may also receive out of the assets of the relevant Fund such additional charges as agreed at normal commercial rates. The Administrator shall be reimbursed out of the assets of the relevant Fund for all reasonable and vouched out-of-pocket expenses incurred by it.

The Administrator earned fees of \$325,913 for the financial period ended June 30, 2022 (June 30, 2021: \$286,533). Administrator fees payable as at June 30, 2022 amounted to \$63,780 (December 31, 2021: \$61,108).

**Depositary fees**

RBC Investor Services Bank S.A., Dublin Branch serves as the Company’s depositary (the “Depositary”). The Depositary shall be entitled to receive an annual oversight fee, accrued on each Dealing Day and calculated and payable monthly in arrears, at an annual rate of up to 2.5 bps of the net asset value of the Fund (plus VAT thereon, if any), subject to a monthly minimum of \$1,167 per Fund (plus VAT, if any).

In addition, the Depositary shall also be entitled to receive, in respect of cash-flow monitoring and reconciliation, a monthly fee of \$550 per Fund (plus VAT, if any).

The combined Depositary fees accrue and are calculated on each Dealing Day and are payable monthly in arrears.

The Depositary shall also be entitled to receive out of the assets of the relevant Fund all agreed sub-custodian fees, transaction charges (which will be charged at normal commercial rates) together with reasonable out-of-pocket expenses (plus VAT thereon, if any) incurred by the Depositary in the performance of its duties under the Depositary Agreement.

The Depositary earned fees of \$209,586 for the financial period ended June 30, 2022 (June 30, 2021: \$239,997). Depositary fees payable as at June 30, 2022 amounted to \$56,627 (December 31, 2021: \$75,186).

**Director fees**

The Constitution provides that the Directors shall be entitled to a fee by way of remuneration for their services at a rate to be determined from time to time by the Directors. Directors affiliated with the Investment Manager are not entitled to a fee. The aggregate amount of Directors’ remuneration in any one year shall not exceed €100,000 without the approval of the Directors. All Directors will be entitled to reimbursement by the Company of expenses properly incurred in connection with the business of the Company or the discharge of their duties.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**5. Fees and Expenses (continued)**

**Director fees (continued)**

The Directors earned fees of \$37,284 for the financial period ended June 30, 2022 (June 30, 2021: \$41,121). Directors' fees payable as at June 30, 2022 amounted to \$43,890 (December 31, 2021: \$6,605).

The Manager assists the Company with payroll compliance services.

**Performance fees – Granahan US Focused Growth Fund**

In respect to Class P and Class P1 Shares, the Investment Manager is entitled to a performance fee (the "Performance Fee") if there is an Outperformance (the net asset value of Class P and Class P1 Shares less the value of the Hurdle (the amount of capital subscribed during the initial offer period adjusted for any subsequent subscriptions, redemptions and dividends paid) as adjusted by the Hurdle Rate (the return of the Russell 2000 Growth Index) (provided that the resulting number is positive)) during a Performance Period (the first Business Day through to the last Business Day of the annual period which commences on 1 April and ends on 31 March, with the exception of the First Performance Period (commences on the close of the initial offer period for Class P1 Shares and ends on 31 March 2021)) and, where Shares are redeemed during a Performance Period, to a pro-rata portion of the Performance Fee accrual (if any) at the time of redemption.

The Performance Fee will be calculated in respect of each Performance Period. The Performance Fee will accrue on each Business Day and the accrual will be reflected in the net asset value per Class P and P1 Share.

Entitlement to a Performance Fee will be calculated if the Outperformance of Class P and P1 Shares on the last Dealing Day of a Performance Period are positive. The Performance Fee will be equal to Outperformance multiplied by 15%.

The Performance Fee is payable on the last Dealing Day of each Performance Period, or if the Class is terminated before the end of a Performance Period, the Dealing Day on which the final redemption of Class P and P1 Shares takes place, or in the case of Shares redeemed during a Performance Period, the accrued Performance Fee in respect of those Shares will be payable within 14 calendar days of the date of redemption (each a "Payment Date"). Any amount of Performance Fee calculated with respect to redeemed Class P and P1 Shares during a Performance Period will be calculated according to the net asset value of the redeemed Shares, and the Hurdle Rate as at the date of redemption (as opposed to at the end of the Performance Period in which the redemption takes place). It is therefore possible that, although the net asset value is not in Outperformance for a full Performance Period, a Performance Fee may be earned by the Investment Manager in respect of Shares redeemed where the redemption took place when the net asset value at redemption was higher than the Hurdle Rate.

Outperformance will be adjusted for any dividends paid by the Fund during the Performance Period.

In the event of an Outperformance on the last Dealing Day of a Performance Period, the value of the Hurdle for the next Performance Period will be reset on 1 April to the net asset value of the Class P and P1 Shares on the last Dealing Day of the preceding Performance Period. If there is no Outperformance on the last Dealing Day of a Performance Period, the value of the Hurdle will not be reset for the next Performance Period and the underperformance of the Class P and P1 Shares in the preceding Performance Period, by reference to the Hurdle adjusted by the Hurdle Rate, will be clawed back (i.e. until under performance is made good) before a Performance Fee becomes due in a subsequent Performance Period. For the avoidance of doubt, any Performance Fee payable in relation to a given Performance Period will not be clawed back.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**5. Fees and Expenses (continued)**

**Performance fees (continued)**

The Performance Fee is calculated based on the net asset value of Class P and P1 Shares and no Shareholder level equalisation is undertaken. This may result in inequalities between Shareholders in relation to the payment of Performance Fees (with some Shareholders paying disproportionately higher performance fees in certain circumstances). Because there is no Shareholder level equalisation, this may also result in certain Shareholders having more of their capital at risk at any given time than other Shareholders. The methodology may, in certain circumstances, result in certain Shareholders being charged a Performance Fee in circumstances where the net asset value per Share of their Shares has not increased over the relevant calculation period as a whole.

*Calculation of the Hurdle for the Performance Period beginning at launch*

The initial value of the Hurdle, upon the launch of the Class P and P1 Shares, will be the net asset value of Class P Shares as at the close of the first Dealing Day of Class P and P1 Shares.

The Performance Fee is payable where there is an Outperformance during the Performance Period, although this may be due to market movements impacting on retained holdings in the Fund rather than specific actions undertaken by the Investment Manager.

Any change to the index relating to the Hurdle Rate will be disclosed in the periodic reports of the Fund.

For the purposes of the Performance Fee calculation, the net asset value shall be calculated before the deduction of any accrual for Performance Fee for that Performance Period, other than Performance Fee accrued in relation to the Class in respect of redemptions during the Performance Period but not yet paid.

As the Performance Fee depends on the performance of the net asset value per Share of Class P and P1 Shares, it is not possible to predict the amount of Performance Fee that will be payable and there is in effect, no maximum Performance Fee as it is impossible to quantify any outperformance in advance.

Investors may request additional information on the way in which the Performance Fee calculation works from the Company.

For the financial period ended June 30, 2022 the performance fees amounted to \$Nil (June 30, 2021: \$1,152,361). Performance fees payable as at June 30, 2022 amounted to \$Nil (December 31, 2021: \$990,243).

**Audit fees**

Remuneration charged by the Company’s audit firm for the period was as follows:

	<b>Total</b>	<b>Total</b>
	<b>June 30, 2022</b>	<b>June 30, 2021</b>
- Audit of statutory financial statements	\$11,922	\$13,149
- Other assurance services	-	-
- Tax advisory services	-	-
- Other non-audit services	-	-
	<b>\$11,922</b>	<b>\$13,149</b>

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**6. Efficient Portfolio Management**

The Company does not currently use Financial Derivative Instruments (“FDIs”) for efficient portfolio management or for investment purposes. The Company may, however, in conjunction with its investment in transferable securities, liquid financial assets, collective investment schemes or other permitted investments in accordance with the UCITS Regulations, indirectly acquire warrants and rights which are issued to such permitted investments.

**7. Transaction Costs**

Transaction costs on the purchase and sale of investments are expensed through the Statement of Operations as incurred. The total amount for the financial period ended June 30, 2022 and June 30, 2021 are shown below:

	<b>Granahan US Focused Growth Fund</b>	<b>Granahan US Focused Growth Fund</b>	<b>Granahan US Small Cap Discoveries Fund</b>	<b>Granahan US Small Cap Discoveries Fund</b>
	<b>June 30, 2022</b>	<b>June 30, 2021</b>	<b>June 30, 2022</b>	<b>June 30, 2021</b>
Total transaction costs on purchases	\$159,124	\$144,506	\$27,100	\$18,951
Total transaction costs on sales	\$251,644	\$111,854	\$37,965	\$11,685
<b>Total transaction costs</b>	<b>\$410,768</b>	<b>\$256,360</b>	<b>\$65,065</b>	<b>\$30,636</b>

	<b>Granahan US SMID Select Fund</b>	<b>Granahan US SMID Select Fund</b>	<b>Total</b>	<b>Total</b>
	<b>June 30, 2022</b>	<b>June 30, 2021</b>	<b>June 30, 2022</b>	<b>June 30, 2021</b>
Total transaction costs on purchases	\$240,108	\$249,460	\$426,332	\$412,917
Total transaction costs on sales	\$220,358	\$172,364	\$509,967	\$295,903
<b>Total transaction costs</b>	<b>\$460,466</b>	<b>\$421,824</b>	<b>\$936,299</b>	<b>\$708,820</b>

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**8. Other expenses and expense reimbursement**

The Company pays the general costs and expenses incurred in its operation. Other expenses paid during the financial period as per the Statement of Operations are shown below:

	<b>Granahan US Focused Growth Fund</b>	<b>Granahan US Focused Growth Fund</b>
	<b>June 30, 2022</b>	<b>June 30, 2021</b>
Bank Interests	\$17,418	\$28,437
Consulting fees	3,121	3,880
Correspondence / Secretarial fees	3,418	4,249
FATCA fees	832	1,035
Investment compliance fees	-	6,358
MIFID fees	565	-
Miscellaneous expenses	2,849	3,212
Registration fees	4,161	5,173
Tax fees / Stock fees	1,486	1,848
<b>Other Expenses</b>	<b>\$33,850</b>	<b>\$54,192</b>

	<b>Granahan US Small Cap Discoveries Fund</b>	<b>Granahan US Small Cap Discoveries Fund</b>
	<b>June 30, 2022</b>	<b>June 30, 2021</b>
Bank Interests	\$1,033	\$1,472
Consulting fees	165	163
Correspondence / Secretarial fees	181	178
FATCA fees	44	43
Investment compliance fees	-	6,001
MIFID fees	30	-
Miscellaneous fees	376	360
Registration fees	220	217
Tax fees / Stock fees	79	77
<b>Other Expenses</b>	<b>\$2,128</b>	<b>\$8,511</b>

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**8. Other expenses and expense reimbursement (continued)**

	Granahan US SMID Select Fund	Granahan US SMID Select Fund
	June 30, 2022	June 30, 2021
Bank Interests	\$8,831	\$9,305
Consulting fees	2,404	2,233
Correspondence / Secretarial fees	2,633	2,446
FATCA fees	641	596
Investment compliance fees	-	4,510
MIFID fees	445	-
Miscellaneous fees	2,198	1,850
Registration fees	3,206	2,978
Tax fees / Stock fees	1,145	1,063
<b>Other Expenses</b>	<b>\$21,503</b>	<b>\$24,981</b>

An expense reimbursement was paid to the Company during the financial period from the Investment Manager for each Fund as outlined in Note 5.

**9. Financial Instruments and Associated Risks**

The securities and instruments in which the Company invests are subject to normal market fluctuations and other risks inherent in investing in such investments and there can be no assurance that any appreciation in value will occur.

The Company's activities expose it to a variety of financial risks: market, liquidity and credit risk. The Investment Manager seeks to minimize these risks through diversification of the investment portfolio in accordance with the specific investment policies and restrictions set out in the Prospectus and Supplement for each Fund. The nature and extent of the financial instruments outstanding at the Statement of Assets and Liabilities date and the risk management policies employed by the Company are discussed below.



**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**9. Financial Instruments and Associated Risks (continued)**

**Market Risk**

Market risk arises mainly from uncertainty about future prices of financial instruments held. It represents the potential loss the Company might suffer through holding market positions in the face of price movements.

The Company is exposed, particularly in its equity assets, to market risk. The Company invests in securities traded on global markets and market risk is a risk to which exposure is unavoidable.

Market risk comprises of market price risk, currency risk and interest rate risk.

**(i) Market price risk**

Market price risk is the risk that the value of a financial instrument will fluctuate as a result of changes in market prices, whether caused by factors specific to an individual investment, its issuer or all factors affecting equity instruments traded in the market.

As the majority of the Company’s investments are carried at fair value with fair value changes recognized in the Statement of Operations, all changes in market conditions will directly affect net income. The risk is mitigated through diversification of the portfolio in investments in various geographic zones and industries.

The investment strategy of the Company is not to replicate a market index and therefore correlation between the return from the Company and any market index is likely to vary. As a result, it is appropriate to use the financial year end portfolio as a risk variable in any market sensitivity analysis. To illustrate the sensitivity of the portfolio based on a reasonably possible estimate of market price movements for a financial year, if the price of each of the equity securities to which the Company had exposure had increased by 5% there would have been the following approximate increases in net assets:

	<b>June 30, 2022</b>	<b>December 31, 2021</b>
	<b>USD</b>	<b>USD</b>
Granahan US Focused Growth Fund	24,947,864	47,058,066
Granahan US Small Cap Discoveries Fund	1,424,596	2,197,305
Granahan US SMID Select Fund	20,487,141	31,679,582

**(ii) Currency Risk**

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. As the Company mainly enters into transactions denominated in USD, the Company’s exposure to foreign currency risk is minimal.

**(iii) Interest Rate Risk**

Interest rate risk is the risk that the value of a financial instrument will fluctuate because of changes in market interest rates. Interest rate risk arises when the Company invests in interest bearing financial instruments. At the financial period ended end, the Company held no interest bearing financial instruments and interest rate risk in relation to cash and cash equivalents is not regarded a material risk.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**9. Financial Instruments and Associated Risks (continued)**

**Liquidity Risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities.

The main liquidity risk to the Company arises from the redemption requests of investors. The Company's Shareholders may redeem their Shares on each dealing day for cash equal to a proportionate share of the relevant Fund's net asset value and it is therefore potentially exposed to the liquidity risk of meeting the daily redemptions by its Shareholders. In order for the Company to meet these requests, the Company may need to dispose of the underlying assets at an inopportune time.

To help manage this risk, if the number of Shares to be redeemed on any dealing day equals 10% or more of the total number of Shares of the Fund in issue on that day the Directors or their delegate may at their discretion refuse to redeem any Shares in excess of 10% of the total number of Shares in issue. If the Directors so refuse, the requests for redemption on such dealing day shall be reduced pro-rata and Shares which are not redeemed by reason of such refusal shall be treated as if a request for redemption had been made in respect of each subsequent dealing day until all Shares to which the original request related have been redeemed.

Each Fund's listed securities are considered readily realizable, as they are quoted on reputable stock exchanges. The Investment Manager monitors the liquidity position on a daily basis.

The tables below show the analysis for the Funds' financial liabilities by relevant maturity groupings based on the remaining financial period ended to the contractual maturity date.

**Granahan US Focused Growth Fund**

<b>June 30, 2022</b>	<b>Less than 1 month</b>	<b>1-3 months</b>	<b>3-12 months</b>	<b>More than 1 year</b>	<b>Total</b>
Payable for securities purchased	\$1,989,499	-	-	-	\$1,989,499
Payable for fund shares redeemed	9,321,544	-	-	-	9,321,544
Payable to Investment Manager	1,268,947	-	-	-	1,268,947
Manager fees payable	30,650	-	-	-	30,650
Directors' fees payable	24,338	-	-	-	24,338
Auditor fees payable	7,783	-	-	-	7,783
Other accrued expenses and other liabilities	80,812	-	-	-	80,812
<b>Total</b>	<b>\$12,723,573</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>\$12,723,573</b>

**GRANAHAN FUNDS PLC**

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**9. Financial Instruments and Associated Risks (continued)**

**Liquidity Risk (continued)**

**Granahan US Focused Growth Fund (continued)**

<b>December 31, 2021</b>	<b>Less than 1 month</b>	<b>1-3 months</b>	<b>3-12 months</b>	<b>More than 1 year</b>	<b>Total</b>
Payable for fund shares redeemed	\$1,513,344	-	-	-	\$1,513,344
Payable to Investment Manager	2,246,137	-	-	-	2,246,137
Manager fees payable	56,066	-	-	-	56,066
Directors' fees payable	3,890	-	-	-	3,890
Auditor fees payable	1,244	-	-	-	1,244
Performance fees payable	990,243	-	-	-	990,243
Other accrued expenses and other liabilities	77,897	-	-	-	77,897
<b>Total</b>	<b>\$4,888,821</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>\$4,888,821</b>

**Granahan US Small Cap Discoveries Fund**

<b>June 30, 2022</b>	<b>Less than 1 month</b>	<b>1-3 months</b>	<b>3-12 months</b>	<b>More than 1 year</b>	<b>Total</b>
Payable for securities purchased	\$1,991,230	-	-	-	\$1,991,230
Payable for fund shares redeemed	8,635	-	-	-	8,635
Payable to Investment Manager	54,495	-	-	-	54,495
Manager fees payable	1,652	-	-	-	1,652
Directors fees payable	1,264	-	-	-	1,264
Auditor fees payable	404	-	-	-	404
Other accrued expenses and other liabilities	15,036	-	-	-	15,036
<b>Total</b>	<b>\$2,072,716</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>\$2,072,716</b>

<b>December 31, 2021</b>	<b>Less than 1 month</b>	<b>1-3 months</b>	<b>3-12 months</b>	<b>More than 1 year</b>	<b>Total</b>
Payable for fund shares redeemed	\$256,070	-	-	-	\$256,070
Payable to Investment Manager	83,626	-	-	-	83,626
Manager fees payable	2,483	-	-	-	2,483
Directors fees payable	181	-	-	-	181
Auditor fees payable	58	-	-	-	58
Other accrued expenses and other liabilities	19,984	-	-	-	19,984
<b>Total</b>	<b>\$362,402</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>\$362,402</b>

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**9. Financial Instruments and Associated Risks (continued)**

**Liquidity Risk (continued)**

**Granahan US SMID Select Fund**

<b>June 30, 2022</b>	<b>Less than 1 month</b>	<b>1-3 months</b>	<b>3-12 months</b>	<b>More than 1 year</b>	<b>Total</b>
Payable for securities purchased	\$2,566,020	-	-	-	\$2,566,020
Payable for fund shares redeemed	4,154,562	-	-	-	4,154,562
Payable to Investment Manager	1,041,536	-	-	-	1,041,536
Manager fees payable	24,580	-	-	-	24,580
Directors fees payable	18,288	-	-	-	18,288
Auditor fees payable	5,848	-	-	-	5,848
Other accrued expenses and other liabilities	59,900	-	-	-	59,900
<b>Total</b>	<b>\$7,870,734</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>\$7,870,734</b>

<b>December 31, 2021</b>	<b>Less than 1 month</b>	<b>1-3 months</b>	<b>3-12 months</b>	<b>More than 1 year</b>	<b>Total</b>
Payable for securities purchased	\$82,349	-	-	-	\$82,349
Payable for fund shares redeemed	344,279	-	-	-	344,279
Payable to Investment Manager	1,526,182	-	-	-	1,526,182
Manager fees payable	35,270	-	-	-	35,270
Directors fees payable	2,534	-	-	-	2,534
Auditor fees payable	810	-	-	-	810
Other accrued expenses and other liabilities	55,564	-	-	-	55,564
<b>Total</b>	<b>\$2,046,988</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>\$2,046,988</b>

**Credit Risk**

Credit risk is the risk that the Company may incur a loss if other parties fail to perform their obligations under the financial instruments which comprise the Fund's investment portfolio. The Company assumes credit risk on parties with whom it trades and it will also bear the risk of settlement default. The Company has a credit risk exposure in relation to its transactions with counterparties such as brokers, banks and other financial intermediaries.

As at June 30, 2022, substantially all of the assets of the Company including investments and cash at bank as noted in the Statement of Assets and Liabilities are held in custody with the Depository. The Company monitors its risk by monitoring the credit quality and financial positions of the Depository. Depending on the requirements of the jurisdictions in which the investments of the Funds are issued, the Depository may use the services of one or more sub-custodians. As at June 30, 2022, the Depository, has a long-term credit rating of AA- with S&P (December 31, 2021: AA-).

The total credit risk for the Funds arising from recognized financial instruments is limited to the value of the Fund's investments shown on the Statements of Assets and Liabilities on pages 22 to 29.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**9. Financial Instruments and Associated Risks (continued)**

**Fair Value of Financial Instruments**

ASC 820 establishes a three-tier fair value hierarchy that prioritises the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

Level 1 – quoted prices in active markets for identical securities.

Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, prepayment speeds, etc.).

Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

The following is a summary of the inputs used as of June 30, 2022 and December 31, 2021 in valuing the Fund’s assets/liabilities carried at fair value:

**Granahan US Focused Growth Fund**

<b>June 30, 2022</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Financial asset at fair value through profit and loss</b>				
<b>Investment in securities</b>				
- Shares	\$498,957,276	-	-	\$498,957,276
<b>Total</b>	<b>\$498,957,276</b>	<b>-</b>	<b>-</b>	<b>\$498,957,276</b>

**Granahan US Focused Growth Fund**

<b>December 31, 2021</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Financial asset at fair value through profit and loss</b>				
<b>Investment in securities</b>				
- Shares	\$941,161,320	-	-	\$941,161,320
<b>Total</b>	<b>\$941,161,320</b>	<b>-</b>	<b>-</b>	<b>\$941,161,320</b>

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**9. Financial Instruments and Associated Risks (continued)**

**Fair Value of Financial Instruments (continued)**

**Granahan US Small Cap Discoveries Fund**

<b>June 30, 2022</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Financial asset at fair value through profit and loss</b>				
<b>Investment in securities</b>				
<b>- Shares</b>	\$28,491,910	-	-	\$28,491,910
<b>Total</b>	<b>\$28,491,910</b>	<b>-</b>	<b>-</b>	<b>\$28,491,910</b>

**Granahan US Small Cap Discoveries Fund**

<b>December 31, 2021</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Financial asset at fair value through profit and loss</b>				
<b>Investment in securities</b>				
<b>- Shares</b>	\$43,946,097	-	-	\$43,946,097
<b>Total</b>	<b>\$43,946,097</b>	<b>-</b>	<b>-</b>	<b>\$43,946,097</b>

**Granahan US SMID Select Fund**

<b>June 30, 2022</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Financial asset at fair value through profit and loss</b>				
<b>Investment in securities</b>				
<b>- Shares</b>	\$409,742,821	-	-	\$409,742,821
<b>Total</b>	<b>\$409,742,821</b>	<b>-</b>	<b>-</b>	<b>\$409,742,821</b>

**Granahan US SMID Select Fund**

<b>December 31, 2021</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Financial asset at fair value through profit and loss</b>				
<b>Investment in securities</b>				
<b>- Shares</b>	\$633,591,636	-	-	\$633,591,636
<b>Total</b>	<b>\$633,591,636</b>	<b>-</b>	<b>-</b>	<b>\$633,591,636</b>

The Funds invest in listed transferable securities whose values are based on quoted prices in active markets. Consequently, these investments are categorized as Level 1.

There were no transfers between levels during the financial period ended June 30, 2022.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**9. Financial Instruments and Associated Risks (continued)**

**Global Exposure**

Per the Central Bank UCITS Regulations, and as part of the risk management and reporting requirements, the Funds must be monitored and measured in accordance with the regulatory requirements. In accordance with the regulatory requirements, global exposure can be calculated in two ways, either Commitment Approach or Value at Risk ("VaR").

The Commitment approach is used by the Funds to calculate global exposure. The Funds held no financial derivative position at any point during the period but, in the event that it does in the future, it would convert the Funds' financial derivative position into an equivalent position of the underlying asset based on the market value of the underlying asset.

**10. Cash and cash equivalents**

Cash comprises current deposits with banks. Cash equivalents are short-term highly liquid investments that are readily convertible to known amounts of cash, are subject to an insignificant risk of change in value and are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes. The cash held on current account with the Depositary at June 30, 2022 represented 2.03% (December 31, 2021: 1.34%) of the net asset value of the Funds.

**11. Related Parties**

The Directors are all non-executive Directors. Jane M. White is co-founder and President and CEO of Granahan Investment Management, Inc. as well as a Managing Director. Brian S. Granahan is Chief Operating Officer and Chief Compliance Officer of Granahan Investment Management, Inc., as well as a Managing Director. Vincent Dodd is the Chairman of the Company and is an Independent Director. Lisa Martensson is an Independent Director. The Directors who are employees of the Investment Manager are not entitled to any remuneration for their services, as disclosed in note 5, for the life of the Company. Directors' remuneration for the financial period ended June 30, 2022 amounted to \$37,284 (June 30, 2021: \$41,121).

No other Directors or any connected person, had any interest in the Shares of the Company, nor have been granted any options in respect of Shares of the Company.

The Investment Manager is deemed to be a related party of the Company. During the financial period ended June 30, 2022, investment manager fees of \$5,143,966 (June 30, 2021: \$6,555,150) were charged to the Company.

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**12. Statement of Net Assets for the financial period**

**Granahan US Focused Growth Fund**

	Net Assets at class level	June 30, 2022 NAV per share
Class A EUR Accumulating	€133,308	€6.06
Class A GBP Accumulating	£12,046,016	£11.21
Class A USD Accumulating	\$82,162,982	\$317.86
Class A USD Distributing	\$5,224,874	\$126.31
Class F EUR Accumulating	€1,273,526	€12.53
Class F GBP Accumulating	£35,232	£8.38
Class I EUR Accumulating	€12,205,617	€6.49
Class I GBP Accumulating	£22,143,287	£10.69
Class I USD Accumulating	\$210,143,042	\$14.54
Class I USD Distributing	\$98,870,684	\$14.53
Class P USD Accumulating*	\$-	\$-
Class P1 USD Accumulating	\$55,979,400	\$8.41

\*This share class was terminated on April 20, 2022.

	Net Assets at class level	December 31, 2021 NAV per share
Class A EUR Accumulating	€204,251	€9.28
Class A GBP Accumulating	£20,321,467	£16.76
Class A USD Accumulating	\$158,499,622	\$528.75
Class A USD Distributing	\$9,924,077	\$210.11
Class F EUR Accumulating	€3,005,572	€19.21
Class F GBP Accumulating	£127,192	£12.55
Class I EUR Accumulating	€66,980,521	€9.93
Class I GBP Accumulating	£33,061,409	£15.97
Class I USD Accumulating	\$248,737,597	\$24.16
Class I USD Distributing	\$176,140,467	\$24.15
Class P USD Accumulating	\$68,868,249	\$23.03
Class P1 USD Accumulating	\$138,490,531	\$13.91

	Net Assets at class level	December 31, 2020 NAV per share
Class A GBP Accumulating	£14,100,229	£16.77
Class A USD Accumulating	\$147,507,584	\$534.53
Class A USD Distributing	\$17,459,375	\$212.41
Class F EUR Accumulating	€1,891,383	€18.12
Class F GBP Accumulating	£127,747	£12.61
Class I GBP Accumulating	£15,408,291	£15.95
Class I USD Accumulating	\$233,116,617	\$24.39
Class I USD Distributing	\$169,902,695	\$24.38
Class P USD Accumulating	\$85,017,911	\$23.00
Class P1 USD Accumulating	\$163,193,452	\$13.88



**GRANAHAN FUNDS PLC**

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**12. Statement of Net Assets for the financial period (continued)**

**Granahan US Small Cap Discoveries Fund**

	Net Assets at class level	June 30, 2022 NAV per share
Class Founder GBP Accumulating	£12,508	£12.28
Class Founder USD Accumulating	\$28,879,083	\$13.69
<b>December 31, 2021</b>		
	Net Assets at class level	NAV per share
Class Founder GBP Accumulating	£24,771	£17.11
Class Founder USD Accumulating	\$45,141,918	\$21.21
<b>December 31, 2020</b>		
	Net Assets at class level	NAV per share
Class Founder GBP Accumulating	£16,652	£16.35
Class Founder USD Accumulating	\$36,342,591	\$20.47

**Granahan US SMID Select Fund**

	Net Assets at class level	June 30, 2022 NAV per share
Class A GBP Accumulating	£420,839	£69.30
Class A GBP Distributing	£49,949	£66.60
Class A USD Accumulating	\$10,770,892	\$62.12
Class I GBP Accumulating	£260,452,730	£149.63
Class I GBP Distributing	£44,282,845	£82.86
Class I USD Accumulating	\$21,276,842	\$72.46
Class I USD Distributing	\$6,568,355	\$72.52
<b>December 31, 2021</b>		
	Net Assets at class level	NAV per share
Class A GBP Accumulating	£3,374,334	£103.24
Class A GBP Distributing	£74,404	£99.21
Class A USD Accumulating	\$18,070,866	\$102.91
Class I GBP Accumulating	£349,402,439	£222.78
Class I GBP Distributing	£66,855,594	£123.36
Class I USD Accumulating	\$38,705,340	\$119.95
Class I USD Distributing	\$12,575,185	\$120.05

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**12. Statement of Net Assets for the financial period ended (continued)**

**Granahan US SMID Select Fund (continued)**

	<b>December 31, 2020</b>	
	<b>Net Assets</b>	<b>NAV</b>
	<b>at class level</b>	<b>per share</b>
Class I GBP Accumulating	£302,811,182	£200.65
Class I GBP Distributing	£4,964,836	£111.12
Class I USD Accumulating	\$7,509,315	\$109.16
Class I USD Distributing	\$595,569	\$109.25

**13. Contingent Liabilities**

The Directors are not aware of any material contingent liabilities as at June 30, 2022.

**14. Soft Commissions**

For the financial period ended June 30, 2022, the Investment Manager received soft commissions from brokers/dealers in consideration for trade execution services for investments of the Funds. These soft commissions were in the form of goods and services such as subscriptions to research services which are of demonstrable benefit to the Shareholders. Examples of these services include: Factset Research Systems, a market data, news and analysis tool for equities research; Bloomberg, market data, news and analysis; William O'Neil, analytical research and tools; Insider Score, analysis of trading activity by insiders; Mackey, tools managing proprietary research. During 2022, commissions paid by the Funds for soft goods and services approximated 36.8%, 28.1% & 34.5% of total fund trading commissions for Granahan US Focused Growth Fund, Granahan US Small Cap Discoveries Fund and Granahan US SMID Select Fund respectively.

**15. Significant Investors**

For the Granahan US Focused Growth Fund, there are three significant investors who hold 10%, 14% and 20% respectively of the total Shares as at June 30, 2022 (December 31, 2021: two significant investors who hold 24% and 13% respectively).

For the Granahan US Small Cap Discoveries Fund, there are four significant investors who hold 14%, 16%, 19% and 19% respectively of the total Shares as at June 30, 2022 (December 31, 2021: four significant investors who hold 19%, 18%, 17% and 13% respectively).

For the Granahan US SMID Select Fund, there are two significant investors who hold 15% and 19% respectively of the total Shares as at June 30, 2022 (December 31, 2021: three significant investors who hold 19%, 15% and 12% respectively).

**NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**16. Significant Events during the financial period**

On January 25, 2022, KBA Consulting Management Limited announced that, subject to regulatory approval, it will become a member of the Waystone Group.

The Board of Directors have noted the recent developments in the Ukraine and the sanctions being imposed on Russia by many countries as a result. Given the absence of exposure in the region, the Board of Directors' view is that those developments and sanctions are unlikely to have a significant direct adverse impact on the Company. Nonetheless, the situation continues to evolve, and it remains difficult at this stage to estimate all direct and indirect impacts which may arise from these emerging developments. The Board of Directors continues to monitor the developments closely and to take all the necessary actions.

**17. Connected Persons**

Any transaction carried out with a UCITS by a management company or depositary to the UCITS, the delegates or sub-delegates of the management company or depositary, and any associated or group company such a management company, depositary, delegate or sub-delegate (“connected persons”) must be carried out as if conducted at arm’s length. Transactions must be in the best interests of the shareholders of the UCITS.

The Directors are satisfied that there are arrangements (evidenced by written procedures) in place, to ensure that the obligations set out above (as referred to in Regulation 43(1) of the Central Bank UCITS Regulations) are applied to all transactions with connected persons, and that transactions with connected parties entered into during the financial year complied with the obligations set out in Regulation 43(1) of the Central Bank UCITS Regulations.

**18. Subsequent Events**

There were no significant events to note after the financial period end.

**19. Exchange Rates**

The following exchange rates were used to translate assets and liabilities into one \$:

	<b>June 30, 2022</b>	<b>December 31, 2021</b>
Canadian Dollar	1.287200	1.264950
Danish Krone	7.097534	-
Euro	-	0.878349
Great British Pound	0.821490	0.738798
Swiss Franc	-	0.911200

**20. Approval of Financial Statements**

The financial statements were approved by the Directors on August 24, 2022.

**SCHEDULE OF MATERIAL PORTFOLIO CHANGES (UNAUDITED)  
For the financial period ended June 30, 2022**

Material portfolio changes are defined as the aggregate purchases of a security exceeding one per cent of the total value of purchases for the period and aggregate sales of a security exceeding one per cent of the total value of sales for the period. At a minimum, the 20 largest purchases and 20 largest sales are to be disclosed.

**GRANAHAN US FOCUSED GROWTH FUND**

<b>Purchases</b>		
<b>Security</b>	<b>Quantity</b>	<b>Cost (in \$)</b>
Etsy Inc	272,232	35,547,551
CoStar Group Inc	383,200	22,074,559
Toast Inc	1,275,280	19,292,379
Coupa Software Inc	156,890	16,245,324
Paylocity Holding Corp	67,112	13,172,351
Paycom Software Inc	30,100	8,965,454
Porch Group Inc	1,410,772	8,526,503
Bumble Inc	368,108	7,614,734
Lovesac Co	150,248	7,399,853
Chegg Inc	285,863	6,119,010
Genius Sports Ltd	1,148,907	5,956,859
Workiva Inc	65,190	5,434,865
SPS Commerce Inc	50,900	5,395,808
Kornit Digital Ltd	119,553	4,876,323
Axon Enterprise Inc	43,666	4,009,839
Liquidity Services Inc	200,153	3,345,597
Stratasys Ltd	134,797	2,739,876
Enphase Energy Inc	16,400	2,624,661
Bright Horizons Family Solutions Inc	27,700	2,495,152
Overstock.com Inc	50,723	2,413,165
Magnite Inc	224,893	2,412,401
Zeta Global Holdings Corp	281,120	2,249,787
Life Time Group Holdings Inc	163,100	2,176,952
Victory Capital Holdings Inc	82,300	2,149,305

**GRANAHAN FUNDS PLC**

**SCHEDULE OF MATERIAL PORTFOLIO CHANGES (UNAUDITED) – continued  
For the financial period ended June 30, 2022**

**GRANAHAN US FOCUSED GROWTH FUND (CONTINUED)**

<b>Sales</b>		
<b>Security</b>	<b>Quantity</b>	<b>Cost (in \$)</b>
Workiva Inc	246,773	26,427,652
Datto Holding Corp	728,383	23,787,687
CoStar Group Inc	284,346	18,557,598
SPS Commerce Inc	142,283	17,215,782
Etsy Inc	145,982	16,064,585
Kornit Digital Ltd	172,929	14,898,767
Axon Enterprise Inc	115,418	13,822,047
Chegg Inc	585,625	12,370,483
Globant SA	42,579	10,570,161
Overstock.com Inc	313,289	10,266,050
Bright Horizons Family Solutions Inc	84,138	9,983,278
Grand Canyon Education Inc	101,023	8,844,820
Cricut Inc	573,930	7,595,711
Bumble Inc	258,205	7,222,702
Zeta Global Holdings Corp	648,850	6,960,154
Enphase Energy Inc	41,654	6,678,110
OSI Systems Inc	78,525	6,593,744
2U Inc	578,620	6,328,692
Paycom Software Inc	20,106	6,320,458
Executive Network Partnering Corp	631,055	6,172,129
OneSpaWorld Holdings Ltd	600,076	5,881,187
Stratasys Ltd	270,072	5,870,682
Life Time Group Holdings Inc	390,696	5,796,517
LivePerson Inc	254,042	5,585,183
Evolent Health Inc	198,389	5,421,349
Sprinklr Inc	452,904	5,397,505
First Watch Restaurant Group Inc	341,733	4,709,194
Lovesac Co	84,823	4,517,260
ThredUp Inc	558,026	4,473,128
Azenta Inc	50,882	4,272,744

**GRANAHAN FUNDS PLC**

**SCHEDULE OF MATERIAL PORTFOLIO CHANGES (UNAUDITED) – continued  
For the financial period ended June 30, 2022**

**GRANAHAN US SMALL CAP DISCOVERIES FUND**

**Purchases**

<b>Security</b>	<b>Quantity</b>	<b>Cost (in \$)</b>
ThredUp Inc	195,300	1,209,273
Portillo's Inc	49,400	1,180,161
Blueprint Medicines Corp	12,800	864,141
Kinsale Capital Group Inc	4,500	850,570
Arcus Biosciences Inc	27,600	752,453
Pacific Biosciences of California Inc	69,500	749,492
Fate Therapeutics Inc	23,700	728,677
Intellia Therapeutics Inc	10,600	692,353
Shockwave Medical Inc	3,600	664,656
Prothena Corp PLC	19,850	659,607
ImmunoGen Inc	129,200	654,269
Revance Therapeutics Inc	50,250	650,904
Perficient Inc	6,200	648,414
BioCryst Pharmaceuticals Inc	37,850	603,375
Natera Inc	12,750	603,343
ChemoCentryx Inc	21,650	592,504
Apellis Pharmaceuticals Inc	13,500	567,452
CorVel Corp	3,750	566,701
Heska Corp	4,400	553,539
American Well Corp	116,250	517,943
Edgio Inc	134,050	476,831
Grocery Outlet Holding Corp	12,850	471,863
Sprout Social Inc	6,650	459,851
Kezar Life Sciences Inc	41,050	445,049
Kiniksa Pharmaceuticals Ltd	40,000	444,808
Stoke Therapeutics Inc	21,450	356,523
Caribou Biosciences Inc	38,350	350,764
CRISPR Therapeutics AG	5,500	342,818
Stoneridge Inc	16,900	325,810
Array Technologies Inc	31,200	315,911
Pulse Biosciences Inc	24,850	313,515
Pliant Therapeutics Inc	28,050	278,069
Zymeworks Inc	35,800	245,322
Magnite Inc	21,950	232,932
Mesa Laboratories Inc	800	221,483
OrthoPediatrics Corp	4,700	210,103

**GRANAHAN FUNDS PLC**

**SCHEDULE OF MATERIAL PORTFOLIO CHANGES (UNAUDITED) – continued  
For the financial period ended June 30, 2022**

**GRANAHAN US SMALL CAP DISCOVERIES FUND (CONTINUED)**

**Sales**

<b>Security</b>	<b>Quantity</b>	<b>Cost (in \$)</b>
Harvard Bioscience Inc	277,703	1,581,038
CONMED Corp	10,010	1,174,544
Computer Task Group Inc	136,541	1,120,313
Hudson Technologies Inc	139,252	1,099,684
Enanta Pharmaceuticals Inc	14,100	803,580
Organogenesis Holdings Inc	104,110	770,358
Sharps Compliance Corp	170,177	770,221
Materion Corp	9,150	743,845
SI-BONE Inc	45,850	697,621
Titan Machinery Inc	26,835	685,918
Alta Equipment Group Inc	49,300	626,697
CEVA Inc	17,723	594,923
Columbus McKinnon Corp	12,950	562,553
James River Group Holdings Ltd	16,850	456,340
Aerie Pharmaceuticals Inc	62,850	452,860
Innovative Industrial Properties Inc	2,150	414,526
Health Catalyst Inc	14,450	412,201
Vericel Corp	11,700	381,184
Spero Therapeutics Inc	32,636	375,136
Rush Enterprises Inc	6,800	366,280
BioCryst Pharmaceuticals Inc	37,850	348,500
BioLife Solutions Inc	11,400	344,086
Pulse Biosciences Inc	45,038	312,315
NeoGenomics Inc	30,700	307,982
Paratek Pharmaceuticals Inc	75,290	294,928
Revance Therapeutics Inc	15,700	288,555
Texas Capital Bancshares Inc	4,550	285,352
Castle Biosciences Inc	6,500	276,152
Distribution Solutions Group Inc	5,845	261,266
Xeris Biopharma Holdings Inc	118,750	257,164
Kinsale Capital Group Inc	1,150	253,766
Luxfer Holdings PLC	11,500	225,135
MacroGenics Inc	17,410	214,967
Kezar Life Sciences Inc	13,550	214,816
Veracyte Inc	7,600	211,499
Renalytix PLC	16,502	204,680

**SCHEDULE OF MATERIAL PORTFOLIO CHANGES (UNAUDITED) – continued**  
**For the financial period ended June 30, 2022**

**GRANAHAN US SMID SELECT FUND**

**Purchases**

<b>Security</b>	<b>Quantity</b>	<b>Cost (in \$)</b>
Kornit Digital Ltd	435,973	27,953,439
Enphase Energy Inc	156,984	21,329,074
Array Technologies Inc	1,713,589	16,298,168
Digital Turbine Inc	527,408	15,404,724
Chegg Inc	514,968	15,146,124
Etsy Inc	98,290	13,993,162
Chart Industries Inc	97,267	13,063,941
EPAM Systems Inc	32,866	9,551,762
Euronet Worldwide Inc	74,665	9,096,062
Silvergate Capital Corp	75,846	8,882,142
Gentherm Inc	119,475	8,499,477
Ameresco Inc	162,794	8,473,260
Ambarella Inc	69,461	8,409,561
Natera Inc	152,760	7,250,979
Repligen Corp	39,467	7,124,457
Inmode Ltd	167,086	6,909,188
Figs Inc	792,862	6,895,774
Magnite Inc	573,042	6,730,720
WillScot Mobile Mini Holdings Corp	182,441	6,322,178
Porch Group Inc	895,588	5,968,697
Revolve Group Inc	113,211	5,028,511
Match Group Inc	59,448	4,675,614
Vita Coco Co Inc	425,686	4,384,107
Littelfuse Inc	16,882	4,326,173
Edgio Inc	1,096,442	4,052,271
Varonis Systems Inc	105,747	3,437,124
Castle Biosciences Inc	112,909	3,143,609
Expedia Group Inc	22,269	3,142,253



**GRANAHAN FUNDS PLC**

**SCHEDULE OF MATERIAL PORTFOLIO CHANGES (UNAUDITED) – continued  
For the financial period ended June 30, 2022**

**GRANAHAN US SMID SELECT FUND (CONTINUED)**

<b>Sales</b>		
<b>Security</b>	<b>Quantity</b>	<b>Cost (in \$)</b>
Evolut Health Inc	848,038	25,424,919
Flex Ltd	1,302,455	22,121,544
Enphase Energy Inc	101,538	19,254,872
Chegg Inc	813,044	16,399,124
Chart Industries Inc	85,361	14,226,050
Lithia Motors Inc	38,642	11,483,868
Darling Ingredients Inc	159,946	10,768,075
Gentherm Inc	106,517	9,629,580
Euronet Worldwide Inc	72,729	9,030,529
Silicon Motion Technology Corp	93,576	8,362,346
Power Integrations Inc	95,306	7,825,004
Newmark Group Inc	443,184	7,057,875
Varonis Systems Inc	155,254	6,916,243
Digital Turbine Inc	126,937	6,475,010
Array Technologies Inc	545,259	6,435,462
Canadian Solar Inc	237,504	6,297,834
Wix.com Ltd	72,387	5,728,057
Green Brick Partners Inc	248,430	5,659,442
Gray Television Inc	257,909	5,432,702
WillScot Mobile Mini Holdings Corp	135,746	5,363,042
Kulicke & Soffa Industries Inc	97,340	5,098,639
Acacia Research Corp	918,637	4,138,542
Pacific Biosciences of California Inc	359,851	3,724,699
Motorcar Parts of America Inc	219,607	3,668,491
Ligand Pharmaceuticals Inc	32,458	3,640,500
Inmode Ltd	154,894	3,624,316
Everbridge Inc	84,748	3,488,296
BioCryst Pharmaceuticals Inc	234,870	3,019,012
Intellia Therapeutics Inc	27,599	2,889,253
Etsy Inc	33,799	2,773,427

**DIRECTORY**

**DIRECTORS**

Jane M. White\* (U.S. Resident)  
Brian S. Granahan\* (U.S. Resident)  
Vincent Dodd\*^ (Irish Resident)  
Lisa Martensson\*^ (Irish Resident)

\* Non-executive Director

^ Independent Director

**REGISTERED OFFICE**

5 George's Dock  
International Financial Services Centre  
Dublin D01 X8N7  
Ireland

**INVESTMENT MANAGER  
AND PROMOTER**

Granahan Investment Management, Inc.  
404 Wyman Street  
Suite 460  
Waltham  
Massachusetts 02451  
U.S.A

**INDEPENDENT AUDITOR**

Deloitte Ireland LLP  
Chartered Accountants & Statutory Audit Firm  
Deloitte & Touche House  
Earlsfort Terrace  
Dublin 2 D02 AY28  
Ireland

**LEGAL COUNSEL**

Dechert  
Second Floor  
5 Earlsfort Terrace  
Dublin 2  
Ireland

**DIRECTORY - continued**

**COMPANY SECRETARY**

Clifton Fund Consulting Limited  
5 George's Dock  
International Financial Service Centre  
Dublin D01 X8N7  
Ireland

**DEPOSITARY**

RBC Investor Services Bank S.A.  
Dublin Branch  
4th Floor,  
One George's Quay Plaza,  
George's Quay  
Dublin 2  
Ireland

**ADMINISTRATOR, REGISTRAR  
AND TRANSFER AGENT**

RBC Investor Services Ireland Limited  
4th Floor,  
One George's Quay Plaza,  
George's Quay  
Dublin 2  
Ireland

**MANAGER**

KBA Consulting Management Limited  
5 George's Dock  
International Financial Service Centre  
Dublin D01 X8N7  
Ireland

**GERMAN INFORMATION AGENT**

GerFis - German Fund Information Service UG (Haftungsbeschränkt)  
Zum Eichhagen 4  
21382 Brietlingen  
Germany

The Prospectus, the Key Investor Information Documents, the Constitution, the annual and semi-annual reports, a list of changes in the composition of the portfolios as well as the issue and redemption prices are available free of charge pursuant to Sec. 297(1) of the German Capital Investment Code from the office of the German information agent (GerFIS - German Fund Information Service UG (Haftungsbeschränkt), Zum Eichhagen 4, 21383 Britlingen, Germany.)